<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Late Night Pyq:Pyt (Medicine-5) - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / Mock Test / Late Night PYQ
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">50</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "id": 84280,
    "choices": [
      {
        "id": 335696,
        "text": "<p><span style=\"font-size:12.0pt;\">Iatrogenic Pneumothorax</span></p>"
      },
      {
        "id": 335697,
        "text": "<p><span style=\"font-size:12.0pt;\">Malposition of central venous catheter</span></p>"
      },
      {
        "id": 335698,
        "text": "<p><span style=\"font-size:12.0pt;\">Air embolism via air embolus</span></p>"
      },
      {
        "id": 335699,
        "text": "<p><span style=\"font-size:12.0pt;\">Cardiac Arrhythmia</span></p>"
      }
    ],
    "text": "<p>A patient experiences sudden breathlessness following a subclavian vein cannulation. Upon examination, there are absent breath sounds and hyper-resonance on percussion on one side of the chest. What is the most likely cause? (NEET PG 2016)</p>",
    "unique_key": "Q6033579",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013178,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><strong>Ans. A) Iatrogenic Pneumothorax</strong></p><p>&nbsp;</p><p>Latrogenic pneumothorax is a type of traumatic pneumothorax that occurs following medical procedures. The clinical presentation of sudden breathlessness after subclavian vein cannulation with absent breath sounds and hyper-resonance on percussion is classic for pneumothorax. The leading causes of iatrogenic pneumothorax include transthoracic needle aspiration, thoracentesis, and the insertion of central intravenous catheters.</p><p>&nbsp;</p><p><strong>Other Options:</strong></p><p>&nbsp;</p><p><strong>Option</strong> B. <strong>Malposition of central venous catheter</strong>: While catheter malposition can cause complications, it would not produce the physical exam findings of absent breath sounds and hyper-resonance characteristic of air in the pleural space.</p><p>&nbsp;</p><p><strong>Option</strong> C. <strong>Air embolism via air embolus</strong>: Air embolism would present with different symptoms including neurological deficits, cardiovascular collapse, or pulmonary symptoms like dyspnea, but would not cause absent breath sounds with hyper-resonance on percussion.</p><p>&nbsp;</p><p><strong>Option</strong> D. <strong>Cardiac Arrhythmia</strong>: Arrhythmias can occur during central line placement but would present with palpitations, dizziness, or hemodynamic instability without the characteristic respiratory exam findings noted in the scenario.</p><p>&nbsp;</p><p><strong>Educational Objective:</strong>&nbsp;</p><p>&nbsp;</p><p>Iatrogenic pneumothorax is a common complication of central venous catheterization, particularly with the subclavian approach, presenting with sudden breathlessness, absent breath sounds, and hyper-resonance on percussion of the affected side.</p>",
    "correct_choice_id": 335696,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "OlderNEETPG"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 74887,
    "choices": [
      {
        "id": 298445,
        "text": "<p><span style=\"font-size:16px;\">a and c</span></p>"
      },
      {
        "id": 298446,
        "text": "<p><span style=\"font-size:16px;\">c only</span></p>"
      },
      {
        "id": 298447,
        "text": "<p><span style=\"font-size:16px;\">a, b and d</span></p>"
      },
      {
        "id": 298448,
        "text": "<p><span style=\"font-size:16px;\">b and c</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:16px;\">Which of the following vaccines is generally not recommended for individuals over 65 years of age? (INICET NOV 2024)</span></p><p>&nbsp;</p><ol style=\"list-style-type:lower-alpha;\"><li><span style=\"font-size:16px;\">Hepatitis B</span></li><li><span style=\"font-size:16px;\">Influenza</span></li><li><span style=\"font-size:16px;\">Human papillomavirus (HPV)</span></li><li><span style=\"font-size:16px;\">Pneumococcal</span></li></ol>",
    "unique_key": "Q7517102",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013068,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. B) c only</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">HPV vaccine is not recommended for individuals over 65 years of age because it is only approved for use up to 45 years of age. The other vaccines mentioned can be safely and effectively administered to elderly individuals based on their risk factors and previous vaccination status.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>a. Hepatitis B vaccine:</strong> This is conditionally indicated in elderly individuals who have not previously received the vaccine and have risk factors.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>b. Influenza vaccine:</strong> This is strongly recommended annually for elderly individuals as they are at high risk for complications from influenza infection.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>d. Pneumococcal vaccine:</strong> This is a crucial vaccine for elderly individuals. The current recommendation in India is to give PCV13 followed by PPSV23 to provide comprehensive protection against pneumococcal infections.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The age-based restrictions for HPV vaccination (approved only up to age 45) and the core vaccines recommended for elderly individuals (pneumococcal, influenza, and conditional hepatitis B vaccination).</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The only non-recommended vaccine in this list for those over 65 years is <strong>HPV</strong>, while pneumococcal, influenza, and hepatitis B vaccines may all be indicated based on individual risk factors and previous vaccination status.</span></p>",
    "correct_choice_id": 298446,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "INICET"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 54265,
    "choices": [
      {
        "id": 216529,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aztreonam </span></span></p>"
      },
      {
        "id": 216530,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vancomycin </span></span></p>"
      },
      {
        "id": 216531,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ceftriaxone </span></span></p>"
      },
      {
        "id": 216532,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Piperacillin</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 45-year-old patient with a penicillin allergy presents with enterococcal endocarditis. Which of the following drugs can be used safely in this patient?</span></span></span>&nbsp;(INICET MAY 2024)</p>",
    "unique_key": "Q4437098",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012952,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> <strong>B) Vancomycin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Enterococci are gram-positive bacteria, and the first-line treatment for enterococcal infections is typically ampicillin. However, in patients with penicillin allergies, vancomycin is the preferred alternative. Vancomycin is a glycopeptide antibiotic that is effective against gram-positive bacteria, including enterococci. It works by inhibiting cell wall synthesis, leading to bacterial cell death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-102729.jpg\" style=\"height:747px; width:700px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Linezolid&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tigecycline (Complicated Skin/Intra-abdominal Infections)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Daptomycin</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. Aztreonam:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This is a monobactam antibiotic that is primarily effective against gram-negative bacteria</span> <span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">particularly in community-acquired pneumonia in ICU patients with a penicillin allergy, <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aztreonam</span></strong> is the best choice.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. Ceftriaxone:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This is a third-generation cephalosporin antibiotic. While effective against some gram-positive bacteria, it is not the preferred choice for enterococcal infections, especially in patients with penicillin allergies due to the risk of cross-reactivity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Piperacillin:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This is a broad-spectrum penicillin antibiotic. It would not be safe to use in a patient with a penicillin allergy due to the risk of a severe allergic reaction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In patients with penicillin allergies who have enterococcal infections, vancomycin is the preferred and safe alternative for treatment.</span></span></span></p>",
    "correct_choice_id": 216530,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "INICET",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 48850,
    "choices": [
      {
        "id": 194983,
        "text": "<p><span style=\"font-size:12.0pt;\">Increased RV/TLC</span></p>"
      },
      {
        "id": 194984,
        "text": "<p><span style=\"font-size:12.0pt;\">Reduced FEV1/FVC</span></p>"
      },
      {
        "id": 194985,
        "text": "<p><span style=\"font-size:12.0pt;\">Increased TLC</span></p>"
      },
      {
        "id": 194986,
        "text": "<p><span style=\"font-size:12.0pt;\">Increased FVC</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">The abnormal preoperative pulmonary function test in a patient with severe kyphoscoliosis includes: (NEET PG 2017)</span></p>",
    "unique_key": "Q4166182",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013179,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><strong>Ans. A) Increased RV/TLC</strong></p><p>&nbsp;</p><p><strong>Explanation:</strong></p><p>&nbsp;</p><p>Severe kyphoscoliosis causes <strong>restrictive pathophysiology</strong> due to chest wall abnormalities. This condition typically shows a <strong>preserved RV but reduced FRC and TLC</strong>. With significant respiratory muscle weakness that accompanies severe kyphoscoliosis, the RV is elevated while TLC is reduced. This pattern leads to an <strong>increased RV/TLC ratio</strong> as the patient cannot fully exhale to normal RV or inhale to normal TLC due to mechanical limitations.</p><p>&nbsp;</p><p><strong>Other Options:</strong></p><p>&nbsp;</p><p><strong>Option B. Reduced FEV1/FVC</strong>: In restrictive disorders like kyphoscoliosis, the FEV1/FVC ratio is typically normal or increased (not reduced). Reduced FEV1/FVC is characteristic of obstructive disorders like asthma or COPD.<br><br>&nbsp;</p><p><strong>Option C. Increased TLC</strong>: Kyphoscoliosis causes a reduction in TLC due to mechanical limitation of chest wall expansion. Restrictive disorders have decreased TLC, not increased.<br><br>&nbsp;</p><p><strong>Option D. Increased FVC</strong>: FVC is reduced in kyphoscoliosis because the restricted chest wall prevents full inspiration. With elevated RV and reduced TLC, the FVC (which equals TLC minus RV) must be reduced, not increased.<br><br>&nbsp;</p><p><strong>Educational Objective:</strong></p><p>&nbsp;</p><p>Severe kyphoscoliosis produces a restrictive pattern with reduced TLC, reduced FVC, normal or increased FEV1/FVC ratio, and an increased RV/TLC ratio due to mechanical limitations of the chest wall and associated respiratory muscle weakness.</p>",
    "correct_choice_id": 194983,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased",
      "OlderNEETPG"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11968,
    "choices": [
      {
        "id": 47837,
        "text": "<p><span style=\"font-size:12.0pt;\">Septic shock</span></p>"
      },
      {
        "id": 47838,
        "text": "<p><span style=\"font-size:12.0pt;\">Cardiogenic shock</span></p>"
      },
      {
        "id": 47839,
        "text": "<p><span style=\"font-size:12.0pt;\">Myxedema coma</span></p>"
      },
      {
        "id": 47840,
        "text": "<p><span style=\"font-size:12.0pt;\">Hyperthyroidism</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A 67-year-old woman presents with altered sensorium, breathlessness, hypotension, and bradycardia. Examination revealed non-pitting edema of the extremities. She has a long-standing history of weight gain, constipation, cold intolerance, and menorrhagia. What is the most likely diagnosis? (INICET NOV 2022)</span></p>",
    "unique_key": "Q9039936",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012955,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Myxedema coma</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The patient presents with several symptoms indicative of severe hypothyroidism. These include altered sensorium, breathlessness, hypotension, bradycardia, non-pitting edema, weight gain, constipation, cold intolerance, and menorrhagia. In hypothyroid patients, a severe, life-threatening condition called myxedema coma can develop. This is characterized by a profound deficiency of thyroid hormones, leading to critical manifestations such as altered mental status, hypothermia, bradycardia, hypotension, and edema.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Myxedema coma requires immediate medical intervention. The treatment of choice involves intravenous administration of thyroxine (IV T4) and IV hydrocortisone. IV hydrocortisone is essential because many patients with myxedema coma have subtle adrenal insufficiency, which can become overt with the initiation of thyroid hormone replacement. This combination helps stabilize the patient's condition and addresses both thyroid and potential adrenal insufficiencies.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Septic shock:</strong> While this condition involves hypotension and altered sensorium, it is usually associated with signs of infection, fever, and a source of sepsis, which are not described in this patient's presentation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Cardiogenic shock:</strong> This condition involves heart failure and typically presents with signs of fluid overload, severe breathlessness, and possibly chest pain, none of which are noted in this patient\u2019s history.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Hyperthyroidism:</strong> The symptoms of hyperthyroidism include weight loss, heat intolerance, tachycardia, and increased bowel movements, which are opposite to the symptoms exhibited by this patient.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Myxedema coma is a severe, life-threatening condition of profound hypothyroidism, characterized by symptoms such as altered sensorium, bradycardia, hypotension, and non-pitting edema. Immediate treatment involves IV thyroxine and IV hydrocortisone to manage both thyroid and potential adrenal insufficiency</span></p>",
    "correct_choice_id": 47839,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "INICET"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 56217,
    "choices": [
      {
        "id": 224285,
        "text": "<p><span style=\"font-size:12.0pt;\">1 and 4</span></p>"
      },
      {
        "id": 224286,
        "text": "<p><span style=\"font-size:12.0pt;\">2 and 3</span></p>"
      },
      {
        "id": 224287,
        "text": "<p><span style=\"font-size:12.0pt;\">2 and 4</span></p>"
      },
      {
        "id": 224288,
        "text": "<p><span style=\"font-size:12.0pt;\">1 and 3</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">What would be seen if the central part of the cord was involved?</span><span style=\"font-size:11pt;\"> (</span><span style=\"font-size:12.0pt;\">INICET MAY 2022)</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\">LMN lesion of upper limbs and trunk and UMN of lower limbs.</span></li><li><span style=\"font-size:12.0pt;\">UMN lesion of upper limbs and trunk and LMN of lower limbs.</span></li><li><span style=\"font-size:12.0pt;\">Bladder and bowel involvement.</span></li><li><span style=\"font-size:12.0pt;\">Posterior tract involvement.</span></li></ol>",
    "unique_key": "Q5974792",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012956,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>D) 1 and 3</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Central cord lesions, such as those seen in conditions like syringomyelia and intramedullary tumors, present with a distinct pattern of neurological deficits due to the anatomical arrangement of the spinal tracts.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>1. LMN lesion of upper limbs and trunk and UMN of lower limbs:</strong> This pattern is common in central cord syndromes, where there is damage to the anterior horn cells leading to lower motor neuron (LMN) lesions in the upper limbs. As the condition progresses, upper motor neuron (UMN) signs may appear in the lower limbs due to the involvement of the corticospinal tract.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>3. Bladder and bowel involvement:</strong> Central cord lesions can affect autonomic functions leading to bladder and bowel dysfunction, especially in cases of extensive or progressive lesions like intramedullary tumors.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>2. UMN lesion of upper limbs and trunk and LMN of lower limbs:</strong> This pattern is not typical for central cord syndromes. Usually, the upper limbs show LMN signs due to the involvement of the anterior horn cells, and the lower limbs show UMN signs.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>4. Posterior tract involvement:</strong> Posterior tracts, which carry fine touch, vibration, and proprioception, are usually spared in central cord syndromes. These tracts are located more dorsally in the spinal cord, away from the central lesion.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Central cord lesions, such as syringomyelia, typically present with LMN signs in the upper limbs, UMN signs in the lower limbs, and can involve bladder and bowel dysfunction, but they do not typically affect the posterior tracts</span></p>",
    "correct_choice_id": 224288,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual",
      "INICET"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 16298,
    "choices": [
      {
        "id": 65152,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Begin treatment with levothyroxine (LT4)</span></span></span></p>"
      },
      {
        "id": 65153,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Measure Thyroxine binding globulin (TBG)</span></span></span></p>"
      },
      {
        "id": 65154,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Order a thyroid radionuclide uptake and scan</span></span></span></p>"
      },
      {
        "id": 65155,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Order thyroid ultrasonography</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old female patient presents with cold intolerance, dry skin, constipation, and on examination slow ankle jerk with a TSH level of 15 IU/L and low T3, and T4. Of the following, the next best step in the management is:&nbsp;</span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">(FMGE DEC 2021)</span></span></span></p>",
    "unique_key": "Q5083334",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013060,
    "difficulty_level": "intermediate",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Begin treatment with levothyroxine (LT4)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient exhibits classic signs and symptoms of hypothyroidism: cold intolerance, dry skin, constipation, and slow reflexes. The elevated TSH level (15 IU/L) and low levels of T3 and T4 confirm the diagnosis. The standard treatment for hypothyroidism is thyroid hormone replacement with levothyroxine, which will help normalize thyroid hormone levels and alleviate symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Measure Thyroxine binding globulin (TBG)</span></strong><span style=\"font-size:12.0pt\">: This is not necessary for the diagnosis or initial management of primary hypothyroidism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Order a thyroid radionuclide uptake and scan</span></strong><span style=\"font-size:12.0pt\">: This is generally used for evaluating hyperthyroidism or thyroid nodules, not primary hypothyroidism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Order thyroid ultrasonography</span></strong><span style=\"font-size:12.0pt\">: Useful if a thyroid nodule or goiter is suspected, but not needed for straightforward hypothyroidism without any palpable thyroid abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Levothyroxine replacement therapy is the appropriate treatment for hypothyroidism confirmed by elevated TSH and low T3 and T4 levels.</span></span></span></p>",
    "correct_choice_id": 65152,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "FMGE",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 73073,
    "choices": [
      {
        "id": 291257,
        "text": "<p><span style=\"font-size:16px;\">Biguanides</span></p>"
      },
      {
        "id": 291258,
        "text": "<p><span style=\"font-size:16px;\">GLP-1 receptor agonists</span></p>"
      },
      {
        "id": 291259,
        "text": "<p><span style=\"font-size:16px;\">SGLT-2 inhibitors</span></p>"
      },
      {
        "id": 291260,
        "text": "<p><span style=\"font-size:16px;\">Sulfonylureas</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:16px;\">Which of the following antidiabetic drugs is preferred in a patient with heart and kidney disease? (FMGE JAN 2025)</span></p>",
    "unique_key": "Q7011056",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013066,
    "difficulty_level": "intermediate",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. C) SGLT-2 inhibitors</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>SGLT-2 inhibitors</strong> (e.g., <strong>dapagliflozin, empagliflozin, canagliflozin</strong>) are the <strong>preferred first-line agents</strong> in diabetic patients with <strong>heart and kidney disease</strong> because they:</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\"><strong>Reduce major adverse cardiovascular events</strong></span></li><li><span style=\"font-size:16px;\"><strong>Decrease heart failure hospitalizations</strong></span></li><li><span style=\"font-size:16px;\"><strong>Slow progression of diabetic kidney disease</strong></span></li><li><span style=\"font-size:16px;\"><strong>Reduce proteinuria and lower blood pressure</strong></span></li><li><span style=\"font-size:16px;\"><strong>Provide cardio-protection independent of glucose control</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. Biguanides (Metformin):</strong> While <strong>first-line for type 2 diabetes</strong>, it does not provide <strong>cardiovascular benefits</strong> and requires <strong>caution in kidney disease</strong> due to the risk of <strong>lactic acidosis</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option B. GLP-1 receptor agonists:</strong> While <strong>cardioprotective</strong>, they <strong>do not provide as strong heart failure or renal benefits</strong> as <strong>SGLT-2 inhibitors</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Sulfonylureas:</strong> Not preferred because:</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\"><strong>High risk of hypoglycemia</strong>, especially in renal disease</span></li><li><span style=\"font-size:16px;\">No proven cardiovascular benefits</span></li><li><span style=\"font-size:16px;\">Possible increased cardiovascular risk with certain sulfonylureas</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>SGLT-2 inhibitors are the preferred antidiabetic agents</strong> in patients with <strong>heart failure and chronic kidney disease (CKD)</strong> due to their <strong>proven cardiovascular and renal benefits</strong>.</span></p>",
    "correct_choice_id": 291259,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "FMGE",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 55356,
    "choices": [
      {
        "id": 220885,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Needle thoracostomy in the 5th intercostal space</span></span></p>"
      },
      {
        "id": 220886,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Urgent tracheostomy</span></span></p>"
      },
      {
        "id": 220887,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">IV fluids</span></span></p>"
      },
      {
        "id": 220888,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">CT scan of the chest</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A patient following a road traffic accident presented with subcutaneous emphysema, respiratory distress, and hypotension. On auscultation, there was no air entry on the right side and a hyper-resonant note was felt on percussion. X-ray is shown. What will be your immediate management? (FMGE JULY 2024)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/30/screenshot-2024-08-30-102422.png\" style=\"height:275px; width:300px\" /></p>",
    "unique_key": "Q3707964",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013065,
    "difficulty_level": "beginner",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A) Needle thoracostomy in the 5th intercostal space</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The clinical presentation of subcutaneous emphysema, respiratory distress, hypotension, absent air entry, and hyper-resonant note on percussion strongly suggests a <strong>tension pneumothorax. </strong>This condition is confirmed by the X-ray, which shows a dark lung field on the right side due to air in the pleural space, a collapsed lung border, and a shift of the mediastinum and trachea to the left side. </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tension pneumothorax is a medical emergency that requires immediate intervention to relieve the pressure in the pleural space. The recommended immediate management is <strong>needle thoracostomy</strong>, which involves the insertion of a wide-bore needle into the 5th intercostal space in the mid-axillary line to rapidly decompress the pleural space, followed by the insertion of a chest drain.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Urgent tracheostomy:</strong> This is not the immediate management for tension pneumothorax. Tracheostomy is typically performed to secure the airway in cases of upper airway obstruction.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. IV fluids:</strong> While IV fluids may be administered to manage hypotension, they do not address the underlying cause of tension pneumothorax and are not the immediate life-saving intervention required.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. CT scan of the chest:</strong> Imaging studies like a CT scan are not performed immediately in cases of tension pneumothorax due to the urgent need for decompression to prevent cardiovascular collapse.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The immediate management for tension pneumothorax is needle thoracostomy in the 5th intercostal space in the mid-axillary line, followed by the insertion of a chest drain.</span></span></p>",
    "correct_choice_id": 220885,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "FMGE",
      "ImageBased",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 24765,
    "choices": [
      {
        "id": 99021,
        "text": "<p><span style=\"font-size:11.0pt;\">Anti-U3 RNP</span></p>"
      },
      {
        "id": 99022,
        "text": "<p><span style=\"font-size:11.0pt;\">Anti-centromere antibody</span></p>"
      },
      {
        "id": 99023,
        "text": "<p><span style=\"font-size:11.0pt;\">Anti-PM-Scl antibody</span></p>"
      },
      {
        "id": 99024,
        "text": "<p><span style=\"font-size:11.0pt;\">Anti-Jo-1 antibody</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A 35-year-old female presents with skin thickening muscle weakness and the peripheries becoming pale on exposure to cold. She is positive for ANA and anti-Scl-70 antibodies. Her creatinine kinase is elevated and muscle biopsy shows perifascicular infiltration. What is the antibody associated with this? (INICET MAY 2023)</span></p>",
    "unique_key": "Q8401708",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013071,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C)&nbsp;Anti-PM-Scl antibody</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The patient presents with features of scleroderma and dermatomyositis overlap syndrome. Anti-PM-Scl antibody is associated with this overlap syndrome, tends to produce nucleolar pattern in your ANA immunofluorescence.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Anti-U3 RNP:</strong> Associated with the diffuse form of scleroderma and are also known as anti-fibrillarin antibodies.</span><br>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Anti-centromere antibody:</strong> Associated with limited scleroderma (CREST syndrome).</span><br>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Anti-Jo-1 antibody:</strong> Associated with antisynthetase syndrome, which predominantly causes interstitial lung disease (ILD), mechanic's hands, myositis, and Raynaud's phenomenon. It is not associated with scleroderma.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Anti-PM-Scl antibody is associated with overlap syndromes involving scleroderma and myositis.</span></p>",
    "correct_choice_id": 99023,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "INICET"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 45822,
    "choices": [
      {
        "id": 182915,
        "text": "<p><span style=\"font-size:12.0pt;\">Obesity</span></p>"
      },
      {
        "id": 182916,
        "text": "<p><span style=\"font-size:12.0pt;\">Urticaria</span></p>"
      },
      {
        "id": 182917,
        "text": "<p><span style=\"font-size:12.0pt;\">Nasal polyp</span></p>"
      },
      {
        "id": 182918,
        "text": "<p><span style=\"font-size:12.0pt;\">Rhinosinusitis</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">Samter\u2019s triad refers to the association of Aspirin-sensitive asthma and: (NEET PG 2017)</span></p>",
    "unique_key": "Q3998969",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012962,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><strong>Ans. C) Nasal polyp</strong></p><p>&nbsp;</p><p><strong>Explanation:</strong></p><p>&nbsp;</p><p>Samter's triad (also called AERD - Aspirin Exacerbated Respiratory Disease) consists of nasal polyps, bronchial asthma, and aspirin hypersensitivity. This classic triad represents a specific phenotype of asthma that often presents with severe symptoms and can be challenging to manage due to the multiple body systems involved and the potential for severe reactions to NSAIDs.</p><p>&nbsp;</p><p><strong>Other Options:</strong></p><p>&nbsp;</p><p><strong>Option A. Obesity</strong>: While obesity can be associated with asthma and may contribute to its severity, it is not a component of Samter's triad. Obesity is a risk factor for OSA and can worsen asthma control, but it's not part of this specific syndrome.</p><p>&nbsp;</p><p><strong>Option B. Urticaria</strong>: Urticaria (hives) is not part of Samter's triad. While aspirin sensitivity can sometimes cause urticaria in some patients, it's not a defining feature of Samter's triad which specifically involves the respiratory tract.</p><p>&nbsp;</p><p><strong>Option D. Rhinosinusitis</strong>: While patients with Samter's triad frequently have chronic rhinosinusitis, the specific defining feature mentioned in the triad is nasal polyps, not rhinosinusitis itself. Nasal polyps represent a more specific pathological finding.</p><p>&nbsp;</p><p><strong>Educational Objective:</strong>&nbsp;</p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Samter's triad is the specific association of three clinical entities: nasal polyps, bronchial asthma, and aspirin hypersensitivity, representing a distinct clinical syndrome requiring specific management considerations.</span></p>",
    "correct_choice_id": 182917,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "OlderNEETPG"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11801,
    "choices": [
      {
        "id": 47170,
        "text": "<p><span style=\"font-size:12.0pt;\">Regardless of ejection fraction and the type of heart failure, the 5-year mortality rate is around 50%.</span></p>"
      },
      {
        "id": 47171,
        "text": "<p><span style=\"font-size:12.0pt;\">Non-cardiovascular death is more in HFrEF as compared to HFpEF.</span></p>"
      },
      {
        "id": 47172,
        "text": "<p><span style=\"font-size:12.0pt;\">ACEi cause cough in 15% and angioedema in 1%.</span></p>"
      },
      {
        "id": 47173,
        "text": "<p><span style=\"font-size:12.0pt;\">AF is common in the elderly and is the cause of stroke in a quarter of stroke cases.</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">All are true regarding heart failure except: (INICET NOV 2021)</span></p>",
    "unique_key": "Q6756854",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012957,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Non-cardiovascular death is more in HFrEF as compared to HFpEF.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Non-cardiovascular death refers to mortality due to causes other than cardiovascular diseases, such as infections, accidents, or malignancies.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The majority of deaths in HFrEF (Heart Failure with reduced Ejection Fraction) are due to cardiovascular causes (85%), and only 15% are due to non-cardiovascular causes.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In contrast, in HFpEF (Heart Failure with preserved Ejection Fraction), 60% of deaths are cardiovascular, and 40% are non-cardiovascular.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Therefore, non-cardiovascular death is actually more prevalent in HFpEF patients compared to HFrEF patients, making option B incorrect.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Regardless of ejection fraction and the type of heart failure, the 5-year mortality rate is around 50%: </strong>This statement is correct. Both HFpEF and HFrEF patients have similar 5-year mortality rates, approximately 50%. This indicates that having a preserved ejection fraction does not necessarily correlate with a better long-term survival rate compared to reduced ejection fraction.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>ACEi cause cough in 15% and angioedema in 1%: </strong>This statement is correct. Angiotensin-Converting Enzyme inhibitors (ACEi) are known to cause a persistent cough in about 15% of patients and angioedema, a more serious but less common side effect, in approximately 1% of patients.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>AF is common in the elderly and is the cause of stroke in a quarter of stroke cases: </strong>This statement is correct. Atrial Fibrillation (AF) is indeed common among elderly patients and is a significant cause of cardioembolic strokes, accounting for about 25% of such cases.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Non-cardiovascular deaths are more common in HFpEF patients compared to HFrEF patients.</span></p>",
    "correct_choice_id": 47171,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "INICET"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11568,
    "choices": [
      {
        "id": 46238,
        "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 3 and 4 correct</span></p>"
      },
      {
        "id": 46239,
        "text": "<p><span style=\"font-size:12.0pt;\">1, 2, and 3 correct</span></p>"
      },
      {
        "id": 46240,
        "text": "<p><span style=\"font-size:12.0pt;\">2 and 3 correct</span></p>"
      },
      {
        "id": 46241,
        "text": "<p><span style=\"font-size:12.0pt;\">1 and 4 correct</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">In atrial fibrillation, choose the correct statements: (INICET MAY 2021)</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\">Novel oral anticoagulants (NOACs) used in the treatment of moderate to severe MS</span></li><li><span style=\"font-size:12.0pt;\">Anticoagulants should be given in patients with ischemic stroke due to atrial fibrillation</span></li><li><span style=\"font-size:12.0pt;\">NOACs are contraindicated in prosthetic valves</span></li><li><span style=\"font-size:12.0pt;\">All patients with atrial fibrillation who are not candidates for cardiac surgery can be started on beta-blockers</span></li></ol>",
    "unique_key": "Q3712308",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012958,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans.&nbsp;C) 2 and 3 correct</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Anticoagulants are indicated for ischemic stroke due to atrial fibrillation. NOACs are contraindicated in patients with prosthetic valves due to a lack of evidence on their efficacy and safety in this population.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">1. NOACs are not used for moderate to severe mitral stenosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">4. Beta-blockers or non-dihydropyridine calcium channel blockers are used for rate control but not universally applicable.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Anticoagulants are used for ischemic stroke in AF, and NOACs are contraindicated in prosthetic valves.</span></p>",
    "correct_choice_id": 46240,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "INICET",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 20258,
    "choices": [
      {
        "id": 80993,
        "text": "<p><span style=\"font-size:12.0pt;\">Diltiazem</span></p>"
      },
      {
        "id": 80994,
        "text": "<p><span style=\"font-size:12.0pt;\">Propranolol</span></p>"
      },
      {
        "id": 80995,
        "text": "<p><span style=\"font-size:12.0pt;\">Esmolol</span></p>"
      },
      {
        "id": 80996,
        "text": "<p><span style=\"font-size:12.0pt;\">Propylthiouracil</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A female patient presents with severe restlessness, palpitations, and tremors to the emergency department. She is a known case of bronchial asthma. On examination, the neck looks swollen. Blood pressure is elevated, and tachycardia is noted. ECG shows atrial fibrillation. Which of the following drugs is used for immediate management in this patient? (NEET PG 2023)</span></p>",
    "unique_key": "Q1754187",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012942,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans.&nbsp;A. Diltiazem</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In a patient with atrial fibrillation and bronchial asthma, the primary goal is to control the heart rate. For rate control in atrial fibrillation, beta-blockers and non-dihydropyridine calcium channel blockers (NDCCBs) like diltiazem or verapamil are commonly used. However, in this case, the patient has bronchial asthma, which makes the use of beta-blockers (such as propranolol and esmolol) less suitable due to their potential to exacerbate asthma symptoms.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Diltiazem is a non-dihydropyridine calcium channel blocker that effectively controls the heart rate without affecting bronchial muscle tone, making it a safer option for patients with asthma. Therefore, diltiazem is the drug of choice for immediate management in this patient.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Propranolol:</strong> Propranolol is a beta-blocker, which can exacerbate bronchial asthma by causing bronchoconstriction. Thus, it is not a suitable choice for patients with asthma.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Esmolol:</strong> Similar to propranolol, esmolol is a beta-blocker and can worsen asthma symptoms due to its bronchoconstrictive effects, making it unsuitable for this patient.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Propylthiouracil:</strong> This medication is used in the management of thyroid storm, a condition associated with severe hyperthyroidism. It is not relevant for rate control in atrial fibrillation and does not address the immediate needs of this patient's condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">For immediate rate control in atrial fibrillation in a patient with bronchial asthma, non-dihydropyridine calcium channel blockers like diltiazem are preferred over beta-blockers to avoid exacerbating asthma symptoms.</span></p>",
    "correct_choice_id": 80993,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "RecentNEETPG",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 24764,
    "choices": [
      {
        "id": 99017,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">3 &rarr; 1 &rarr; 2</span></span></p>"
      },
      {
        "id": 99018,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">3 &rarr; 2 &rarr; 1</span></span></p>"
      },
      {
        "id": 99019,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2 &rarr; 1 &rarr; 3</span></span></p>"
      },
      {
        "id": 99020,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1 &rarr; 2 &rarr; 3</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Order in which the following heart sounds are heard from superior to inferior on the left side chest wall? </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">(INICET MAY 2023)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">1.Pulmonary area</span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">2.Erb&rsquo;s area</span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">3.Mitral area</span></span></span></p>",
    "unique_key": "Q9702202",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012954,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) 1 &rarr; 2 &rarr; 3</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The heart sounds are heard in the following order from superior to inferior on the left side chest wall: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pulmonary area: 2nd intercostal space near the sternum </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Erb&rsquo;s area (2<sup>nd</sup> aortic area): 3rd intercostal space near the sternum </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Mitral area: 4th intercostal space at the midclavicular line (away from sternum).</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The correct order from superior to inferior for heart sounds on the left side chest wall is pulmonary area, Erb&rsquo;s area, and mitral area.</span></span></span></p>",
    "correct_choice_id": 99020,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "INICET"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 54260,
    "choices": [
      {
        "id": 216509,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Almost never seen in heart with normal morphology</span></span></p>"
      },
      {
        "id": 216510,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IV Digoxin can be used for ventricular rate control</span></span></p>"
      },
      {
        "id": 216511,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DC Cardioversion is required in all cases</span></span></p>"
      },
      {
        "id": 216512,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Discrepancy in HR and PR is a clinically reliable criteria for diagnosis</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 38-year-old man collapsed and was brought to the emergency. ECG was taken and a diagnosis of atrial fibrillation (AF) was made. Which of the following is true?</span></span></span>&nbsp;(INICET MAY 2024)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-101221.jpg\" style=\"height:248px; width:500px\" /></span></span></span></p>",
    "unique_key": "Q7883146",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013069,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> <strong>B) IV Digoxin can be used for ventricular rate control</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Atrial fibrillation (AF) is characterized by an irregularly irregular rhythm without distinct P waves on ECG, which confirms the diagnosis. Each of the provided options needs to be evaluated for accuracy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">IV Digoxin can be used for ventricular rate control</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">.</span> <span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This is the correct statement. IV Digoxin is used for rate control in AF, particularly in patients with heart failure. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">If the patient is stable and not in acute heart failure, beta-blockers or non-dihydropyridine calcium channel blockers like verapamil or diltiazem are preferred.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Almost never seen in heart with normal morphology</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This statement is incorrect. Atrial fibrillation can occur in morphologically normal hearts. Studies indicate that 15-35% of AF cases can be seen in individuals with structurally normal hearts, although it is more common in those with conditions such as heart failure or left atrial enlargement.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-family:Calibri,sans-serif\"><strong style=\"font-size:11pt\"><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><strong style=\"font-size:11pt\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">DC Cardioversion is required in all cases</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\">:</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.6667px; font-style:normal\">&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\">This statement is incorrect. DC cardioversion is reserved for unstable patients or for rhythm control in selected chronic cases. It is not required for all AF cases.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-family:Calibri,sans-serif\"><strong style=\"font-size:11pt\"><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong><strong style=\"font-size:11pt\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Discrepancy in HR and PR is a clinically reliable criteria for diagnosis</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\">:</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:14.6667px; font-style:normal\">&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\">This statement is incorrect. While a pulse deficit (difference between heart rate and pulse rate) can suggest AF, it is not a reliable diagnostic criterion as it can be observed in other conditions such as frequent ventricular premature contractions, cardiac tamponade, and severe heart failure.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IV Digoxin can be effectively used for ventricular rate control in patients with atrial fibrillation, especially in those with heart failure.</span></span></p>",
    "correct_choice_id": 216510,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "ImageBased",
      "INICET"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11778,
    "choices": [
      {
        "id": 47078,
        "text": "<p><span style=\"font-size:12.0pt;\">1 and 2</span></p>"
      },
      {
        "id": 47079,
        "text": "<p><span style=\"font-size:12.0pt;\">2, 3 and 4</span></p>"
      },
      {
        "id": 47080,
        "text": "<p><span style=\"font-size:12.0pt;\">1, 2 and 4</span></p>"
      },
      {
        "id": 47081,
        "text": "<p><span style=\"font-size:12.0pt;\">2 and 5</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A 23-year-old medical student developed epistaxis that resolved spontaneously. He has been afebrile for the last 24 hours and his platelet count is 14,000/\u00b5L. His BP is 110/70 mm of Hg and there is a 28% rise in hematocrit. What should be the management? (INICET NOV 2020)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">1. Give 4 units of platelets</span></p><p><span style=\"font-size:12.0pt;\">2. Give plenty of oral fluids</span></p><p><span style=\"font-size:12.0pt;\">3. Give IV fluids</span></p><p><span style=\"font-size:12.0pt;\">4. Keep under observation</span></p><p><span style=\"font-size:12.0pt;\">5. Discharge the patient</span></p>",
    "unique_key": "Q2541925",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013176,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B)&nbsp;2, 3 and 4</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The patient likely has Dengue Hemorrhagic Fever, indicated by a significant rise in hematocrit, which suggests plasma leakage during the critical phase of the illness. The management strategy includes:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Statement 2. Oral fluids </strong>to maintain hydration but must be balanced to avoid fluid overload.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Statement&nbsp;3. IV fluids </strong>are essential for the management of severe dengue to correct the plasma leakage and prevent shock.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Statement&nbsp;4. Observation </strong>is crucial to monitor for further complications such as dengue shock syndrome.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. 1 and 2</strong>: Platelet transfusion is generally reserved for severe bleeding or very low platelet counts (typically &lt;10,000/\u00b5L without bleeding). This patient's platelet count, while low, does not alone justify transfusion without signs of active or severe bleeding.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. 1, 2 and 4</strong>: Includes unnecessary platelet transfusion without the clear presence of severe bleeding or extremely low platelet counts.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. 2 and 5</strong>: Discharging the patient is inappropriate given the potential for rapid deterioration during the critical phase of dengue fever.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In dengue hemorrhagic fever, management focuses on careful fluid management and close observation during the critical phase to prevent or manage complications such as shock. Platelet transfusions are not routinely given based solely on low counts but are reserved for cases of significant clinical bleeding or extremely low platelet counts.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Note </strong>- There is no correlation between bleeding manifestation and platelet count.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Reference - Dengue Case management for Clinicians- CDC</strong></span></p>",
    "correct_choice_id": 47079,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "INICET",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 73072,
    "choices": [
      {
        "id": 291253,
        "text": "<p><span style=\"font-size:16px;\">Propranolol</span></p>"
      },
      {
        "id": 291254,
        "text": "<p><span style=\"font-size:16px;\">Sumatriptan</span></p>"
      },
      {
        "id": 291255,
        "text": "<p><span style=\"font-size:16px;\">Amitriptyline</span></p>"
      },
      {
        "id": 291256,
        "text": "<p><span style=\"font-size:16px;\">Verapamil</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:16px;\">A 35-year-old woman presents with recurrent migraines characterized by throbbing unilateral headaches, nausea, and photophobia. She has not responded to over-the-counter analgesics. Which of the following medications is most appropriate for acute treatment? (FMGE JAN 2025)</span></p>",
    "unique_key": "Q1420219",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012949,
    "difficulty_level": "intermediate",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. B) Sumatriptan</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Sumatriptan</strong> is the <strong>most appropriate choice</strong> for <strong>acute migraine treatment</strong>. It belongs to the <strong>triptan</strong> class (<strong>5-HT\u2081B/1D receptor agonists</strong>) and:</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\"><strong>Works through vasoconstriction</strong> and <strong>blocking pain pathways</strong></span></li><li><span style=\"font-size:16px;\"><strong>Most effective when taken early in a migraine attack</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\">The patient presents with <strong>classic migraine symptoms</strong> (<strong>unilateral throbbing headache, nausea, photophobia</strong>) and has failed <strong>over-the-counter medications</strong>, making <strong>triptans the next step in management</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. Propranolol:</strong> Incorrect. <strong>Beta-blocker used for migraine prophylaxis</strong> rather than acute treatment</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option C. Amitriptyline:</strong> Incorrect. <strong>Tricyclic antidepressant used for migraine prevention</strong>, not acute attacks</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Verapamil:</strong> Incorrect. <strong>Calcium channel blocker used for cluster headache prophylaxis</strong>, not migraines</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Triptans (e.g., sumatriptan) are first-line medications</strong> for <strong>acute treatment of moderate-to-severe migraines</strong> that have <strong>not responded to over-the-counter analgesics</strong>.</span></p>",
    "correct_choice_id": 291254,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "FMGE",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11814,
    "choices": [
      {
        "id": 47222,
        "text": "<p><span style=\"font-size:12.0pt;\">Natalizumab</span></p>"
      },
      {
        "id": 47223,
        "text": "<p><span style=\"font-size:12.0pt;\">Ocrelizumab</span></p>"
      },
      {
        "id": 47224,
        "text": "<p><span style=\"font-size:12.0pt;\">Fingolimod</span></p>"
      },
      {
        "id": 47225,
        "text": "<p><span style=\"font-size:12.0pt;\">Alemtuzumab</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Which of the following drugs is preferred in the management of primary progressive multiple sclerosis? (INICET NOV 2021)</span></p>",
    "unique_key": "Q5965774",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013174,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Ocrelizumab</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Ocrelizumab is the preferred drug for the management of primary progressive multiple sclerosis (PPMS). PPMS is a form of multiple sclerosis characterized by a gradual progression of neurological symptoms without relapses. The reference paragraph highlights that Ocrelizumab is the only drug that has been shown to be effective in treating PPMS based on recent clinical trials. Ocrelizumab is a monoclonal antibody that targets CD20-positive B cells, which are believed to play a significant role in the pathogenesis of multiple sclerosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A.</strong> <strong>Natalizumab:</strong> This drug is used primarily for relapsing-remitting multiple sclerosis (RRMS). It works by inhibiting the migration of immune cells into the central nervous system, but it has not been shown to be effective in PPMS.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C</strong>. <strong>Fingolimod:</strong> While Fingolimod is effective in treating RRMS, it is not the preferred treatment for PPMS. Fingolimod works by modulating sphingosine-1-phosphate receptors to prevent lymphocytes from reaching the central nervous system.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D</strong>. <strong>Alemtuzumab:</strong> This drug is used for RRMS and works by depleting circulating T and B lymphocytes. It has not been demonstrated to be effective in treating PPMS.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Ocrelizumab is the only drug currently shown to be effective in the management of primary progressive multiple sclerosis (PPMS).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Remember</strong> - The drug that has been shown to be effective in treating secondary progressive multiple sclerosis (SPMS) is Siponimod, which is a sphingosine-1-phosphate receptor agonist.</span></p>",
    "correct_choice_id": 47223,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "INICET",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11569,
    "choices": [
      {
        "id": 46242,
        "text": "<p><span style=\"font-size:12.0pt;\">Area postrema syndrome</span></p>"
      },
      {
        "id": 46243,
        "text": "<p><span style=\"font-size:12.0pt;\">Acute Myelitis</span></p>"
      },
      {
        "id": 46244,
        "text": "<p><span style=\"font-size:12.0pt;\">Focal epilepsy</span></p>"
      },
      {
        "id": 46245,
        "text": "<p><span style=\"font-size:12.0pt;\">Optic neuritis</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a major diagnostic criterion of neuromyelitis Optica? (INICET MAY 2021)</span></p>",
    "unique_key": "Q2781351",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013175,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans.&nbsp;C) Focal epilepsy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Neuromyelitis optica (NMO) spectrum disorder, also known as Devic's disease, is an autoimmune condition characterized by severe, recurrent episodes of optic neuritis and myelitis. The diagnostic criteria for NMO spectrum disorders include specific clinical syndromes. &nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Focal epilepsy</strong> is not a diagnostic criterion for NMO. While seizures can occur in NMOSD due to brain lesions, focal epilepsy itself is not a major diagnostic feature.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span><br>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Area postrema syndrome&nbsp;</strong>&nbsp;is major criteria. This is characterized by intractable nausea, vomiting, or hiccups, which is due to lesions in the area postrema of the brainstem.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Acute myelitis</strong> is major criteria. Inflammation of the spinal cord, usually longitudinally extensive (spanning three or more vertebral segments).</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Optic neuritis</strong> is major criteria. This involves inflammation of the optic nerve, leading to vision loss or impairment, often affecting both eyes.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorder (NMOSD)</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Most Common Core Clinical criteria:</strong></span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\">Longitudinal extensive transverse myelitis (acute myelitis)</span></li><li><span style=\"font-size:12.0pt;\">Optic neuritis, often bilateral</span></li><li><span style=\"font-size:12.0pt;\">Area postrema syndrome</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Less Common Clinical Criteria:</strong></span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\">Acute brainstem syndrome</span></li><li><span style=\"font-size:12.0pt;\">Acute diencephalic syndrome, which can manifest as symptomatic narcolepsy</span></li><li><span style=\"font-size:12.0pt;\">Symptomatic cerebral syndrome (symptomatic cerebral lesions)</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Some patients with NMOSD may have anti-NMO IgG antibody positivity, also known as anti-aquaporin 4 antibody (AQP4-IgG).</span></p>",
    "correct_choice_id": 46244,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual",
      "INICET"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11774,
    "choices": [
      {
        "id": 47062,
        "text": "<p><span style=\"font-size:12.0pt;\">ABCD</span></p>"
      },
      {
        "id": 47063,
        "text": "<p><span style=\"font-size:12.0pt;\">CABD</span></p>"
      },
      {
        "id": 47064,
        "text": "<p><span style=\"font-size:12.0pt;\">ABDC</span></p>"
      },
      {
        "id": 47065,
        "text": "<p><span style=\"font-size:12.0pt;\">ACBD</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">Correct sequence after p wave: (INICET NOV 2020)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">A- 'a' wave</span></p><p><span style=\"font-size:12.0pt;\">B- 1st heart sound</span></p><p><span style=\"font-size:12.0pt;\">C-Rapid filling of ventricles</span></p><p><span style=\"font-size:12.0pt;\">D- 't' wave</span></p>",
    "unique_key": "Q4905345",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012959,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C)&nbsp;ABDC</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Following the P wave, which represents atrial depolarization leading to atrial contraction:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>A- 'a' wave </strong>occurs as a result of atrial contraction, pushing blood into the ventricles.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>B- 1st heart sound </strong>is produced by the closure of the mitral and tricuspid valves at the beginning of ventricular systole.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>D- 't' wave </strong>represents the repolarization of the ventricles, indicating the beginning of ventricular relaxation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>C- Rapid filling of ventricles </strong>follows as the ventricles relax and the atrioventricular valves open, allowing blood to flow from the higher pressure atria to the relaxed ventricles.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Electrical events precede mechanical events in cardiac homeostasis</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">P wave\u2192 Atrial contraction (a wave).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">QRS\u2192 ventricular contraction (C wave)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">T wave\u2192 Ventricular relaxation (Early rapid filling (Y descent)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Reference - Harrison/Cardiology/Clinical/ chap 239</strong></span></p>",
    "correct_choice_id": 47064,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "INICET"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11266,
    "choices": [
      {
        "id": 45030,
        "text": "<p><span style=\"font-size:12.0pt;\">Normal pressure hydrocephalus</span></p>"
      },
      {
        "id": 45031,
        "text": "<p><span style=\"font-size:12.0pt;\">Frontotemporal dementia</span></p>"
      },
      {
        "id": 45032,
        "text": "<p><span style=\"font-size:12.0pt;\">Parkinson disease</span></p>"
      },
      {
        "id": 45033,
        "text": "<p><span style=\"font-size:12.0pt;\">Creutzfeldt-Jakob disease</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">An elderly woman is brought to the OPD with complaints of behavioral change, a history of multiple falls, urinary incontinence, and dementia. What is your diagnosis? (NEET PG 2020)</span></p>",
    "unique_key": "Q1090654",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013056,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A.</strong> <strong>Normal pressure hydrocephalus</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Normal pressure hydrocephalus (NPH) is characterized by the triad of dementia, gait disturbance (typically apraxia or magnetic gait), and urinary incontinence. This condition often involves enlargement of the cerebral ventricles due to cerebrospinal fluid accumulation, which can exert pressure on surrounding brain structures, particularly affecting the frontal lobes responsible for cognitive and urinary control. The clinical presentation aligns well with the symptoms described in the patient.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Frontotemporal dementia:</strong> This condition often presents with prominent personality changes and language difficulties rather than the classic triad seen in NPH. Falls are less commonly associated with this form of dementia in its early stages.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Parkinson disease:</strong> Typically presents with motor symptoms such as tremors, rigidity, and bradykinesia. While dementia can occur in later stages, it is not typically accompanied by urinary incontinence and would not explain the early presence of falls as the primary symptom.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Creutzfeldt-Jakob disease:</strong> Known for rapid progression of neurological symptoms including dementia, myoclonus (sudden muscle spasms), and significant motor dysfunction. It progresses much faster than what is typically seen in NPH.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">NPH is characterized by Dementia, Apraxia/Magnetic gait with urinary incontinence due to frontal lobe dysfunction</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Reference - Harrison/Dementia/Chap 434</strong></span></p>",
    "correct_choice_id": 45030,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "RecentNEETPG"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11262,
    "choices": [
      {
        "id": 45014,
        "text": "<p><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Restrictive disease</span></span></p>"
      },
      {
        "id": 45015,
        "text": "<p><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Obstructive disease</span></span></p>"
      },
      {
        "id": 45016,
        "text": "<p><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal lung function</span></span></p>"
      },
      {
        "id": 45017,
        "text": "<p><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Interstitial lung disease</span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">On performing a pulmonary function test, reduction in FEV1/FVC is characteristic of: (NEET PG 2019)</span></span></p>",
    "unique_key": "Q3575475",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013055,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Obstructive disease</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A reduction in the FEV1/FVC ratio (Forced Expiratory Volume in 1 second / Forced Vital Capacity) is characteristic of obstructive lung diseases. This ratio is a key indicator used to differentiate between obstructive and restrictive lung patterns on pulmonary function tests. In obstructive diseases, such as chronic obstructive pulmonary disease (COPD), asthma, and bronchiectasis, there is a disproportionate reduction in FEV1 relative to FVC due to airflow limitation and air trapping.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/03/screenshot-2024-10-03-094610.png\" style=\"height:211px; width:500px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Restrictive disease:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In restrictive lung diseases, both FEV1 and FVC are reduced proportionally, often leading to a normal or even increased FEV1/FVC ratio. Restrictive diseases include conditions such as pulmonary fibrosis and other interstitial lung diseases.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Normal lung function:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal lung function would typically show an FEV1/FVC ratio within the normal range, which is generally above 0.7 in healthy adults.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Interstitial lung disease:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This condition is a type of restrictive lung disease where there is a reduction in lung volumes, but the FEV1/FVC ratio is typically normal or increased, not reduced.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1/FVC reduction implies obstruction. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FEV1/FVC Increased or normal &ndash; <strong>Restrictive lung disease</strong></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decrease in Maximum Mid-expiratory flow (MMEF) i.e., FEV25%-75% - <strong>Small airway disease</strong></span></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 45015,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "OlderNEETPG"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 50950,
    "choices": [
      {
        "id": 203341,
        "text": "<p><span style=\"font-size:12.0pt;\">2, 3&nbsp;</span></p>"
      },
      {
        "id": 203342,
        "text": "<p><span style=\"font-size:12.0pt;\">4, 5&nbsp;</span></p>"
      },
      {
        "id": 203343,
        "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 3, 4, 5&nbsp;</span></p>"
      },
      {
        "id": 203344,
        "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 3, 4&nbsp;</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old man presented with an acute onset of chest pain radiating to the left arm and diaphoresis. His ECG and cardiac biomarkers show non-ST elevation myocardial infarction. Which of the following will be used in the treatment of this patient? (</span>INICET Nov 2023)</p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">1. Atorvastatin&nbsp;</span></p><p><span style=\"font-size:12.0pt;\">2. Aspirin&nbsp;</span></p><p><span style=\"font-size:12.0pt;\">3. Clopidogrel&nbsp;</span></p><p><span style=\"font-size:12.0pt;\">4. Low molecular weight heparin&nbsp;</span></p><p><span style=\"font-size:12.0pt;\">5. Alteplase</span></p>",
    "unique_key": "Q9418706",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013070,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D)&nbsp;1, 2, 3, 4</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation: &nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In the management of non-ST elevation myocardial infarction (NSTEMI), several medications are routinely used to reduce the risk of further ischemic events and manage the condition effectively:</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\">Atorvastatin: High-intensity statin therapy is recommended to lower cholesterol levels and stabilize atherosclerotic plaques.</span></li><li><span style=\"font-size:12.0pt;\">Aspirin: This antiplatelet agent is essential for reducing clot formation and preventing further arterial blockage.</span></li><li><span style=\"font-size:12.0pt;\">Clopidogrel: Another antiplatelet agent, often used in combination with aspirin, to provide dual antiplatelet therapy (DAPT), which is beneficial in preventing further ischemic events.</span></li><li><span style=\"font-size:12.0pt;\">Low molecular weight heparin: Anticoagulant therapy, such as enoxaparin, is crucial in preventing thrombus formation and managing NSTEMI. Enoxaparin is typically administered subcutaneously at a dose of 1 mg/kg twice daily.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Option:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">5. Alteplase: This thrombolytic agent is used in the management of ST-elevation myocardial infarction (STEMI) when percutaneous coronary intervention (PCI) is not immediately available. It is not indicated for NSTEMI due to the lack of ST elevation and the associated risks of bleeding without significant benefit.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">For NSTEMI management, the treatment includes Atorvastatin, Aspirin, Clopidogrel, and Low molecular weight heparin. Thrombolytic agents like Alteplase are reserved for STEMI with specific indications.</span></p>",
    "correct_choice_id": 203344,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "INICET",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 50948,
    "choices": [
      {
        "id": 203333,
        "text": "<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Admit and give IV levofloxacin&nbsp; </span></span></span></span></p>"
      },
      {
        "id": 203334,
        "text": "<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treat at home with oral Amox-clav </span></span></span></span></p>"
      },
      {
        "id": 203335,
        "text": "<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Admit and give IV ceftriaxone&nbsp; </span></span></span></span></p>"
      },
      {
        "id": 203336,
        "text": "<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Admit and give IV ceftriaxone and IV levofloxacin&nbsp;</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man was brought after a fall. He has a fever and confusion. On examination, he had a cough with rales. The patient was also tachypneic. How will you manage this patient? (</span></span>INICET Nov 2023)</p>",
    "unique_key": "Q2790895",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012953,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Admit and give IV ceftriaxone and IV levofloxacin</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This patient is likely suffering from community-acquired pneumonia (CAP) and presents with confusion, fever, cough with rales, and tachypnea. Given his age (65 years) and symptoms, a CURB-65 score calculation is necessary. The CURB-65 score assigns points based on confusion, urea level, respiratory rate, blood pressure, and age &ge; 65. Here, the patient scores at least 3 points (confusion, tachypnea, age &ge; 65), indicating a need for hospital admission and potentially ICU care.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In managing CAP with a high CURB-65 score, empirical antibiotic therapy typically includes a combination of a beta-lactam (like ceftriaxone) and a macrolide or a respiratory fluoroquinolone (like levofloxacin). This combination is chosen to cover the most common pathogens, including Streptococcus pneumoniae and atypical bacteria.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Admit and give IV levofloxacin:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Levofloxacin alone is a potent respiratory fluoroquinolone but may not provide sufficient broad-spectrum coverage </span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">&nbsp; </span></span></p>\r\n\r\n<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Treat at home with oral Amox-clav:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Given the patient&#39;s high CURB-65 score, home treatment is inappropriate. Oral antibiotics like Amox-clav are insufficient for severe CAP needing hospitalization.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">&nbsp; </span></span></p>\r\n\r\n<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.&nbsp; Admit and give IV ceftriaxone:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While IV ceftriaxone is effective against many CAP pathogens, the addition of IV levofloxacin provides better coverage, especially for atypical organisms.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:10pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In elderly patients with high CURB-65 scores and suspected severe community-acquired pneumonia, hospital admission and combination antibiotic therapy (such as IV ceftriaxone and IV levofloxacin) are essential for effective management.</span></span></span></span></p>",
    "correct_choice_id": 203336,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "INICET",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 47545,
    "choices": [
      {
        "id": 189791,
        "text": "<p><span style=\"font-size:12.0pt;\">Fomepizole</span></p>"
      },
      {
        "id": 189792,
        "text": "<p><span style=\"font-size:12.0pt;\">Flumazenil</span></p>"
      },
      {
        "id": 189793,
        "text": "<p><span style=\"font-size:12.0pt;\">Diazepam</span></p>"
      },
      {
        "id": 189794,
        "text": "<p><span style=\"font-size:12.0pt;\">Naloxone</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A male patient was brought to the emergency room with complaints of headache, vomiting, and blurring of vision after he consumed some locally produced spirit. Which of the following is used for the treatment of his condition?&nbsp;</span>(FMGE JULY 2023)</p>",
    "unique_key": "Q2532950",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013063,
    "difficulty_level": "beginner",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Fomepizole</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The symptoms of headache, vomiting, and blurring of vision after consuming locally produced spirit suggest methanol poisoning. Methanol is commonly found in illicit liquor and can cause severe toxicity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The treatment for methanol poisoning involves inhibiting the <strong>enzyme alcohol dehydrogenase,</strong> which is responsible for converting methanol into its toxic metabolites, such as formic acid and formaldehyde.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Fomepizole (4-methylpyrazole)&nbsp;</strong>is the drug of choice as it is a competitive inhibitor of alcohol dehydrogenase, preventing the formation of these toxic metabolites.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Alternative treatment \u2013 IV Ethanol (competitive blocker of alcohol dehydrogenase)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Flumazenil:&nbsp;</strong>Used as an antidote for benzodiazepine overdose.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Diazepam:&nbsp;</strong>Used in the management of alcohol withdrawal and as a sedative but not as an antidote for methanol poisoning.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Naloxone:&nbsp;</strong>Used as an antidote for opioid overdose.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Fomepizole is the preferred treatment for methanol poisoning, as it inhibits alcohol dehydrogenase, preventing the formation of toxic metabolites.</span></p>",
    "correct_choice_id": 189791,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "FMGE",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 47543,
    "choices": [
      {
        "id": 189783,
        "text": "<p><span style=\"font-size:12.0pt;\">Antiparasitic drugs</span></p>"
      },
      {
        "id": 189784,
        "text": "<p><span style=\"font-size:12.0pt;\">Steroids</span></p>"
      },
      {
        "id": 189785,
        "text": "<p><span style=\"font-size:12.0pt;\">Antiepileptics</span></p>"
      },
      {
        "id": 189786,
        "text": "<p><span style=\"font-size:12.0pt;\">Anti-edema treatment</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A patient presents with seizures. His CT head reveals multiple parenchymal cysts. Which of the following is not a part of immediate management in the next 24 hours?&nbsp;</span>(FMGE JULY 2023)</p>",
    "unique_key": "Q2977921",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012946,
    "difficulty_level": "intermediate",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Antiparasitic drugs</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Antiparasitic drugs</strong>, such as <strong>albendazole or praziquantel</strong>, are not part of the immediate management. Starting antiparasitic treatment without adequate anti-inflammatory coverage (steroids) can worsen the patient's condition by increasing inflammation due to the destruction of the cysts.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Antiparasitic therapy (<strong>albendazole or praziquantel or both</strong>) can be initiated later, typically along with steroids, to mitigate this risk.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Doses \u2013</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Albendazole \u2013 15 mg/Kg/day (Max. of 1200 mg/day)</span></li><li><span style=\"font-size:12.0pt;\">Praziquantel \u2013 50-100 mg/kg/day in 3 divided doses</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Note \u2013 Severe disease or &gt;2 cyst \u2013 Combination of both drug in doses of 15 mg/kg/day Albendazole + 50mg/kg/day Praziquantel</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In a case of neurocysticercosis, the immediate management of a patient presenting with seizures and multiple parenchymal cysts on CT includes:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Steroids:&nbsp;</strong>To reduce inflammation and surrounding edema caused by the cysts.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Antiepileptics:&nbsp;</strong>To control seizures, which are the most common presentation of neurocysticercosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Anti-edema treatment:&nbsp;</strong>To manage any cerebral edema and prevent further complications.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In the immediate management of neurocysticercosis presenting with seizures, antiepileptics, steroids, and anti-edema treatment are essential, while antiparasitic drugs can be started later.</span></p>",
    "correct_choice_id": 189783,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "FMGE",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11582,
    "choices": [
      {
        "id": 46294,
        "text": "<p><span style=\"font-size:12.0pt;\">Kaposi's sarcoma</span></p>"
      },
      {
        "id": 46295,
        "text": "<p><span style=\"font-size:12.0pt;\">Melanoma</span></p>"
      },
      {
        "id": 46296,
        "text": "<p><span style=\"font-size:12.0pt;\">Invasive cervical carcinoma</span></p>"
      },
      {
        "id": 46297,
        "text": "<p><span style=\"font-size:12.0pt;\">Non-Hodgkin\u2019s lymphoma</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">AIDS-defining malignancies include all except: </span><span style=\"font-size:11pt;\">(</span><span style=\"font-size:12.0pt;\">INICET MAY 2022)</span></p>",
    "unique_key": "Q2042846",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013073,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>B) Melanoma</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Melanoma</strong>, on the other hand, is a type of skin cancer primarily associated with UV exposure and is not considered an AIDS-defining malignancy. Although people with HIV/AIDS might have a higher risk of developing melanoma due to their immunocompromised state, it is not specifically used to define AIDS.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">AIDS-defining malignancies are specific types of cancer that are more likely to occur in people with AIDS. These cancers are used in the clinical definition of AIDS because they are directly associated with the immunosuppression caused by the HIV virus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Kaposi's sarcoma</strong>: This cancer is caused by Human Herpesvirus 8 (HHV-8) and is one of the most common AIDS-defining cancers. It manifests as vascular tumors that can appear on the skin and internal organs.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Invasive cervical carcinoma</strong>: This cancer is linked to the Human Papillomavirus (HPV) and is considered an AIDS-defining condition due to the increased risk in immunocompromised individuals.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Non-Hodgkin\u2019s lymphoma</strong>: Particularly the diffuse large B-cell lymphoma (DLBCL) and primary central nervous system (CNS) lymphoma, are common in AIDS patients due to the compromised immune system.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Melanoma is not considered an AIDS-defining malignancy, unlike Kaposi's sarcoma, invasive cervical carcinoma, and non-Hodgkin\u2019s lymphoma.</span></p>",
    "correct_choice_id": 46295,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "INICET"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 16297,
    "choices": [
      {
        "id": 65148,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Observation and monitoring</span></span></span></p>"
      },
      {
        "id": 65149,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous labetalol</span></span></span></p>"
      },
      {
        "id": 65150,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous thrombolysis</span></span></span></p>"
      },
      {
        "id": 65151,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Endovascular Therapy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient comes with a BP of 160/100 mmHg and left-sided facial paralysis and weakness for 8 hours. Her CT is shown below. What is the next step?&nbsp;(FMGE DEC 2021)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/30/screenshot-2024-09-30-131322.png\" style=\"height:343px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q2213805",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012943,
    "difficulty_level": "intermediate",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Observation and monitoring</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient presents with a blood pressure of 160/100 mmHg and left-sided facial paralysis and weakness. These symptoms are indicative of a cerebrovascular event, likely an ischemic stroke. However, the key factor here is the duration of symptoms (8 hours).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In cases of ischemic stroke, intravenous thrombolysis is typically considered if the patient presents within 4.5 hours of symptom onset. Beyond this window, the risk of hemorrhage increases, making thrombolysis less safe. Endovascular therapy might be considered up to 24 hours for certain patients, but this is based on specific criteria which are not met here given the stable presentation and manageable BP.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The CT scan is crucial to rule out hemorrhage and other contraindications for thrombolysis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the CT scan, the finding of hypodensity in the right basal ganglia region suggests an infarct.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">As the CT scan shows no hemorrhage, the priority is to manage the patient&rsquo;s symptoms and blood pressure while monitoring for any changes. Intravenous labetalol may be used to control significantly high blood pressure (&gt;185/110) in acute stroke, but in this scenario, the BP of 160/100 mmHg is not critically high and doesn&#39;t necessitate immediate aggressive BP management. Thus, observation and monitoring are recommended.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Intravenous labetalol</span></strong><span style=\"font-size:12.0pt\">: While it can be used to manage hypertension in acute stroke, the BP here is not critically high. Unnecessary reduction of BP can decrease cerebral perfusion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Intravenous thrombolysis</span></strong><span style=\"font-size:12.0pt\">: Recommended only if within 4.5 hours of symptom onset. In this case, the patient is beyond that window.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Endovascular Therapy</span></strong><span style=\"font-size:12.0pt\">: Since the patient is presenting beyond 6 hours, it&#39;s crucial to obtain CT perfusion data to evaluate eligibility for endovascular therapy. Additionally, assessing eligibility for endovascular therapy requires information on large vessel occlusion from CT angiogram. Without these critical data, the decision for endovascular therapy cannot be made.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For a patient presenting with ischemic stroke symptoms beyond 4.5 hours of onset and a blood pressure of 160/100 mmHg, observation and monitoring are appropriate unless further specific imaging indicates a different course of action.</span></span></span></p>",
    "correct_choice_id": 65148,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "FMGE",
      "ImageBased",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11263,
    "choices": [
      {
        "id": 45018,
        "text": "<p><span style=\"font-size:12.0pt;\">Hyperthyroidism</span></p>"
      },
      {
        "id": 45019,
        "text": "<p><span style=\"font-size:12.0pt;\">Hypoparathyroidism</span></p>"
      },
      {
        "id": 45020,
        "text": "<p><span style=\"font-size:12.0pt;\">Hyperparathyroidism</span></p>"
      },
      {
        "id": 45021,
        "text": "<p><span style=\"font-size:12.0pt;\">Cushing's syndrome</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">Calcitonin levels are increased in: (NEET PG 2019)</span></p>",
    "unique_key": "Q9036256",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013181,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C. Hyperparathyroidism</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Calcitonin, a hormone secreted by the thyroid gland, is involved in the regulation of calcium levels in the body. In conditions where there is an increase in parathyroid hormone (PTH) levels, such as in hyperparathyroidism, there is a corresponding increase in blood calcium levels. The body responds to this hypercalcemia by increasing the secretion of calcitonin to help lower the calcium levels back to normal.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Hyperthyroidism:&nbsp;</strong>While hyperthyroidism involves the thyroid gland, it does not typically result in increased calcitonin levels. Hyperthyroidism mainly increases thyroid hormones like thyroxine (T4) and triiodothyronine (T3), not calcitonin.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Hypoparathyroidism:&nbsp;</strong>This condition is characterized by decreased PTH levels, leading to hypocalcemia (low calcium levels), not hypercalcemia that would stimulate calcitonin production.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Cushing's syndrome:&nbsp;</strong>Cushing's syndrome involves an excess of cortisol, a steroid hormone, and does not directly affect calcitonin levels.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Increased calcitonin levels are typically seen in response to hypercalcemia, as seen in hyperparathyroidism. This is a compensatory mechanism to help maintain calcium homeostasis.</span></p>",
    "correct_choice_id": 45020,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "OlderNEETPG"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 16181,
    "choices": [
      {
        "id": 64684,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Inclusion body myositis</span></span></span></p>"
      },
      {
        "id": 64685,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Dermatomyositis</span></span></span></p>"
      },
      {
        "id": 64686,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Polymyositis</span></span></span></p>"
      },
      {
        "id": 64687,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Scleroderma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 50-year-old woman presented with difficulty in activities like climbing stairs, getting up from a chair, and combing hair. Violaceous erythema of the upper eyelids was noted. What is the most probable diagnosis? (FMGE JAN 2023)</span></span></span></p>",
    "unique_key": "Q1970641",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012945,
    "difficulty_level": "intermediate",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>B) Dermatomyositis</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The patient&#39;s symptoms of difficulty in climbing stairs, getting up from a chair, and combing hair suggest proximal muscle weakness, a key feature of myopathy. The presence of violaceous erythema of the upper eyelids, known as heliotrope rash, strongly indicates dermatomyositis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Dermatomyositis is characterized by both muscle inflammation and distinctive skin rashes, and it is commonly associated with <strong>anti-Mi-2 antibodies</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. Inclusion body myositis:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Typically presents with asymmetric muscle weakness and does not usually involve skin rashes like dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. Polymyositis:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Also involves proximal muscle weakness but lacks the characteristic skin manifestations seen in dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Scleroderma:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Primarily affects the skin with hardening and tightening but does not typically present with proximal muscle weakness or the specific rash of dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Proximal muscle weakness combined with characteristic skin rashes, such as heliotrope rash, is indicative of dermatomyositis.</span></span></span></p>",
    "correct_choice_id": 64685,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "FMGE"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 92150,
    "choices": [
      {
        "id": 366916,
        "text": "<p><span style=\"font-size:14.0pt;\">It helps in determining the duration of antibiotic therapy</span></p>"
      },
      {
        "id": 366917,
        "text": "<p><span style=\"font-size:14.0pt;\">It helps in identifying which empirical antibiotics to be given</span></p>"
      },
      {
        "id": 366918,
        "text": "<p><span style=\"font-size:14.0pt;\">It can be used to confirm source of infection</span></p>"
      },
      {
        "id": 366919,
        "text": "<p><span style=\"font-size:14.0pt;\">It is used to differentiate bacterial from fungal cause</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt;\">A patient underwent cardiac surgery and was admitted to the ICU. He later developed ventilator-associated pneumonia and was started on empirical antibiotics. A few hours later, the patient developed acute kidney injury (AKI). Serum procalcitonin was sent. Which of the following statements regarding procalcitonin is correct? (INICET MAY 2025)</span></p>",
    "unique_key": "Q4253971",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012950,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:14.0pt;\"><strong>Ans. A) It helps in determining the duration of antibiotic therapy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\">Procalcitonin is most useful in determining the duration of antibiotic therapy, particularly in ICU settings. It serves as a biomarker that helps clinicians decide when to de-escalate or discontinue antibiotics rather than when to start them. Procalcitonin levels decrease as bacterial infections resolve, making it valuable for guiding antibiotic stewardship and preventing unnecessary prolonged antibiotic courses. This is especially important in ICU patients where antibiotic de-escalation is crucial to prevent resistance and reduce adverse effects. While procalcitonin is a marker of inflammation, it is non-specific like CRP and primarily helps with the \"when to stop\" rather than \"when to start\" antibiotics question.</span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Option B. It helps in identifying which empirical antibiotics to be given:</strong> Procalcitonin does not guide the choice of specific empirical antibiotics. The selection of empirical antibiotics is guided by the clinical situation, suspected pathogens, local resistance patterns, and patient factors, not by procalcitonin levels.</span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Option C. It can be used to confirm source of infection:</strong> Procalcitonin cannot confirm the source of infection. It is elevated in any inflammatory condition and is very non-specific, similar to CRP. Clinical evaluation, imaging, and cultures are needed to identify infection sources.</span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Option D. It is used to differentiate bacterial from fungal cause:</strong> Procalcitonin cannot reliably differentiate between bacterial and fungal infections. While it may be somewhat helpful in distinguishing bacterial from viral infections, it is not useful for bacterial versus fungal differentiation.</span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\">Procalcitonin is primarily used as a biomarker to guide antibiotic de-escalation and determine the duration of antibiotic therapy, particularly in ICU settings.</span></p>",
    "correct_choice_id": 366916,
    "solution_audio": null,
    "solution_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/92150/Ini_Cet_May_2025_Medicine_Q_-_11new.mp4",
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "top",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased",
      "TreatmentBased"
    ],
    "explanation_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/92150/Ini_Cet_May_2025_Medicine_Q_-_11new.mp4",
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 84278,
    "choices": [
      {
        "id": 335692,
        "text": "<p><span style=\"font-size:12.0pt;\">Rofecoxib</span></p>"
      },
      {
        "id": 335693,
        "text": "<p><span style=\"font-size:12.0pt;\">Metoprolol</span></p>"
      },
      {
        "id": 335694,
        "text": "<p><span style=\"font-size:12.0pt;\">Fenofibrate</span></p>"
      },
      {
        "id": 335695,
        "text": "<p><span style=\"font-size:12.0pt;\">Losartan</span></p>"
      }
    ],
    "text": "<p>Which of the following medications has been associated with an increased risk of cardiac mortality? (NEET PG 2016)</p>",
    "unique_key": "Q9945433",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012961,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><strong>Ans. A) Rofecoxib</strong></p><p>&nbsp;</p><p>Rofecoxib (a COX-2 inhibitor) has been associated with increased cardiac mortality. NSAIDs, especially selective COX-2 inhibitors, create a small but definite increased risk of myocardial infarction and mortality in patients with ischemic heart disease. When NSAID use is unavoidable in IHD patients, clinicians should select agents with the lowest cardiovascular risk profile and use them at the lowest effective dose for the shortest duration possible.</p><p>&nbsp;</p><p><strong>Other Options:</strong></p><p>&nbsp;</p><p><strong>Option B. Metoprolol</strong>: Metoprolol is a selective \u03b21-blocker that reduces mortality in patients with ischemic heart disease. Beta blockers are first-line therapy for managing stable ischemic heart disease and have demonstrated benefits in reducing mortality and reinfarction rates after myocardial infarction.</p><p>&nbsp;</p><p><strong>Option C. Fenofibrate</strong>:&nbsp; Fenofibrate has not been documented as increasing cardiac mortality in IHD patients. It functions primarily to raise HDL cholesterol and lower triglycerides as part of lipid management therapy.</p><p>&nbsp;</p><p><strong>Option D. Losartan</strong>: Losartan is an angiotensin receptor blocker (ARB) that is recommended for patients with IHD. ARBs are preferred agents for hypertension control in stable ischemic heart disease patients, especially those with reduced ejection fraction (&lt;50%), diabetes mellitus, or chronic kidney disease.</p><p>&nbsp;</p><p><strong>Educational Objective:</strong>&nbsp;</p><p>&nbsp;</p><p>NSAIDs, particularly COX-2 inhibitors like rofecoxib, increase cardiovascular risk in patients with ischemic heart disease and should be avoided when possible in this population.</p>",
    "correct_choice_id": 335692,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "OlderNEETPG",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11964,
    "choices": [
      {
        "id": 47821,
        "text": "<p><span style=\"font-size:12.0pt;\">Metabolic alkalosis with high anion gap</span></p>"
      },
      {
        "id": 47822,
        "text": "<p><span style=\"font-size:12.0pt;\">Metabolic acidosis with high anion gap</span></p>"
      },
      {
        "id": 47823,
        "text": "<p><span style=\"font-size:12.0pt;\">Metabolic acidosis with normal anion gap</span></p>"
      },
      {
        "id": 47824,
        "text": "<p><span style=\"font-size:12.0pt;\">Metabolic alkalosis with normal anion gap</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">Which of the following electrolyte abnormalities is seen in methanol intoxication? (INICET NOV 2022)</span></p>",
    "unique_key": "Q1600804",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013072,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Metabolic acidosis with high anion gap</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Methanol intoxication leads to metabolic acidosis with a high anion gap &amp; high osmolal gap. Methanol is metabolized in the body to formic acid, which is a strong acid. The accumulation of formic acid in the bloodstream results in an increase in hydrogen ion concentration, leading to acidosis. The high anion gap indicates that there are unmeasured anions (such as formate) contributing to the acidosis. In addition to causing a high anion gap, methanol intoxication also leads to a high osmolal gap, which is another diagnostic clue in cases of toxic alcohol ingestion.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Metabolic alkalosis with high anion gap:&nbsp;</strong>This statement is incorrect because methanol intoxication does not cause alkalosis. Instead, it causes acidosis due to the production of formic acid.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Metabolic acidosis with normal anion gap:&nbsp;</strong>This statement is incorrect because the acidosis caused by methanol intoxication is characterized by a high anion gap due to the accumulation of formate, a byproduct of methanol metabolism.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Metabolic alkalosis with normal anion gap:&nbsp;</strong>This statement is incorrect because methanol intoxication leads to acidosis, not alkalosis, and the anion gap is elevated, not normal.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Methanol intoxication causes metabolic acidosis with a high anion gap due to the accumulation of formic acid.</span></p>",
    "correct_choice_id": 47822,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "INICET"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 55355,
    "choices": [
      {
        "id": 220881,
        "text": "<p><span style=\"font-size:12pt;\">Nebulization with budesonide</span></p>"
      },
      {
        "id": 220882,
        "text": "<p><span style=\"font-size:12pt;\">Long-term O2 therapy</span></p>"
      },
      {
        "id": 220883,
        "text": "<p><span style=\"font-size:12pt;\">Pneumococcal vaccine</span></p>"
      },
      {
        "id": 220884,
        "text": "<p><span style=\"font-size:12pt;\">Positive Pressure Ventilation</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt;\">65-year-old lady with a history of COPD and cor pulmonale presents with breathlessness and frequent exacerbations. Which of the following will improve survival in this patient?<strong>&nbsp;</strong> (FMGE JULY 2024)</span></p>",
    "unique_key": "Q8669474",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012948,
    "difficulty_level": "intermediate",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) Long-term O2 therapy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">For patients with Chronic Obstructive Pulmonary Disease (COPD), there are only a few interventions proven to improve survival. These include smoking cessation, long-term oxygen therapy (LTOT) for those who qualify, and lung volume reduction surgery (LVRS) in selected patients. LTOT is particularly beneficial for patients with severe hypoxemia, as it helps maintain adequate oxygen levels, reducing the risk of heart failure and other complications associated with chronic hypoxemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In this case, the presence of cor pulmonale, which is a condition secondary to long-standing COPD leading to right heart failure, further strengthens the indication for LTOT. This therapy can help manage symptoms and prevent further deterioration.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A.</strong> <strong>Nebulization with budesonide:</strong> While this may help in managing symptoms of COPD by reducing inflammation and preventing exacerbations, it does not have a proven impact on improving overall survival.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Pneumococcal vaccine:</strong> This can reduce the risk of pneumococcal infections, which are common in COPD patients, but it does not directly improve survival in the long-term management of COPD.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong> <strong>Positive Pressure Ventilation:&nbsp;</strong> This can be useful in managing acute exacerbations of COPD or chronic respiratory failure, but it is not typically used as a long-term therapy to improve survival.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Long-term oxygen therapy (LTOT) is one of the few interventions that improve survival in patients with COPD, especially those with severe hypoxemia and complications like cor pulmonale.</span></p>",
    "correct_choice_id": 220882,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "FMGE",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 92151,
    "choices": [
      {
        "id": 366920,
        "text": "<p><span style=\"font-size:14.0pt;\">A, B&nbsp;</span></p>"
      },
      {
        "id": 366921,
        "text": "<p><span style=\"font-size:14.0pt;\">B, C&nbsp;</span></p>"
      },
      {
        "id": 366922,
        "text": "<p><span style=\"font-size:14.0pt;\">A, B, C&nbsp;</span></p>"
      },
      {
        "id": 366923,
        "text": "<p><span style=\"font-size:14.0pt;\">D only</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:14.0pt;\">Which of the following statements about Multiple Sclerosis are incorrect? (INICET MAY 2025)</span></p><p>&nbsp;</p><ol style=\"list-style-type:upper-latin;\"><li><span style=\"font-size:14.0pt;\">70% of patients with MS develop Optic Neuritis during the course of illness&nbsp;</span></li><li><span style=\"font-size:14.0pt;\">Oral steroids are first line for acute relapses&nbsp;</span></li><li><span style=\"font-size:14.0pt;\">Loss of colour and depth perception is proportional to loss of visual acuity&nbsp;</span></li><li><span style=\"font-size:14.0pt;\">Fundus examination can be normal</span></li></ol>",
    "unique_key": "Q7806988",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013067,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:14.0pt;\"><strong>Ans. C) A, B, C</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>A. 70% of patients with MS develop Optic Neuritis during the course of illness</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:14.0pt;\">This is correct. Optic neuritis is indeed very common in MS, occurring in approximately 70% of patients at some point during their disease course. It may be the initial presenting symptom in 15-20% of cases.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>B. Oral steroids are first line for acute relapses</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:14.0pt;\">This is incorrect. Intravenous methylprednisolone (not oral steroids) is the first-line treatment for acute MS relapses. The ONTT (Optic Neuritis Treatment Trial) showed that oral prednisone alone may actually increase the risk of recurrent optic neuritis. High-dose IV steroids are preferred for acute attacks.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>C. Loss of colour and depth perception is proportional to loss of visual acuity</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:14.0pt;\">This is incorrect. In optic neuritis, loss of color vision (dyschromatopsia) and contrast sensitivity often occurs disproportionately to the loss of visual acuity. Patients may have relatively preserved visual acuity but significant impairment in color discrimination, particularly red desaturation.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Correct Statement:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>D. Fundus examination can be normal</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:14.0pt;\">This is correct. In retrobulbar optic neuritis (which is the most common form in MS), the fundus examination is typically normal initially because the inflammation is behind the optic disc. This is classically described as \"the patient sees nothing, and the doctor sees nothing.\"</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14.0pt;\">In Multiple Sclerosis, 50% of patients develop optic neuritis during illness course, IV steroids are first-line for acute relapses, and color/depth perception loss is out of proportion to visual acuity loss in optic neuritis.</span></p>",
    "correct_choice_id": 366922,
    "solution_audio": null,
    "solution_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/92151/INI_CET_May_2025_Medicine_Q_-_12.mp4",
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "top",
    "tags": [
      "Factual",
      "InvestigationBased",
      "TreatmentBased"
    ],
    "explanation_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/92151/INI_CET_May_2025_Medicine_Q_-_12.mp4",
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 74886,
    "choices": [
      {
        "id": 298441,
        "text": "<p><span style=\"font-size:16px;\">Female sex workers</span></p>"
      },
      {
        "id": 298442,
        "text": "<p><span style=\"font-size:16px;\">Long distance truck drivers</span></p>"
      },
      {
        "id": 298443,
        "text": "<p><span style=\"font-size:16px;\">Male having sex with male</span></p>"
      },
      {
        "id": 298444,
        "text": "<p><span style=\"font-size:16px;\">IV drug abusers</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:16px;\">Which of the following groups is not considered a core risk factor group for HIV transmission? (INICET NOV 2024)</span></p>",
    "unique_key": "Q1660988",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012951,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. B) Long-distance truck drivers</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The core risk groups for HIV transmission are populations that primarily transmit the disease to bridge populations, who then transmit it to the general population. In endemic countries like India, addressing these core groups is crucial for reducing HIV transmission rates. The core high-risk groups include female sex workers, men who have sex with men (MSM), transgender populations, and injectable drug users.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Long-distance truck drivers are considered a <strong>bridge population</strong> rather than a core risk group. While they are important in the transmission chain, they act as intermediaries between core risk groups and the general population.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image_93334Gb.png\" width=\"655\" height=\"686\"></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image_dcL1dbs.png\" width=\"1157\" height=\"161\"></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. Female sex workers:</strong> Incorrect. This is a core risk group according to NACO 2024 data and is one of the primary populations targeted for HIV prevention.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option C. Male having sex with male (MSM):</strong> Incorrect. MSM is a core high-risk group that requires focused intervention for HIV prevention.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. IV drug abusers:</strong> Incorrect. Injectable drug users are considered a core high-risk group for HIV transmission.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The distinction between core risk groups and bridge populations in HIV transmission:</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Core risk groups include:</strong></span></p><p>&nbsp;</p><ol><li><span style=\"font-size:16px;\">Female sex workers</span></li><li><span style=\"font-size:16px;\">Men who have sex with men (MSM)</span></li><li><span style=\"font-size:16px;\">Transgender populations</span></li><li><span style=\"font-size:16px;\">Injectable drug users</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Bridge populations</strong>, like truck drivers and migrants, serve as intermediaries in disease transmission.</span></p>",
    "correct_choice_id": 298442,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual",
      "INICET"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11221,
    "choices": [
      {
        "id": 44850,
        "text": "<p><span style=\"font-size:12.0pt;\">Distal bronchiectasis</span></p>"
      },
      {
        "id": 44851,
        "text": "<p><span style=\"font-size:12.0pt;\">Cough</span></p>"
      },
      {
        "id": 44852,
        "text": "<p><span style=\"font-size:12.0pt;\">Wheezing</span></p>"
      },
      {
        "id": 44853,
        "text": "<p><span style=\"font-size:12.0pt;\">Raised serum lgE levels</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a common feature of ABPA?</span> <span style=\"font-size:12.0pt;\">(NEET PG 2018)</span></p>",
    "unique_key": "Q4525949",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013054,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A. Distal bronchiectasis</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">ABPA is diagnosed based<strong> </strong>on<strong> ISHAM criteria </strong>which requires the following:</span></p><ol><li><span style=\"font-size:12.0pt;\"><strong>Predisposing Condition:</strong> Asthma/Cystic fibrosis</span></li><li><span style=\"font-size:12.0pt;\"><strong>Mandatory Criteria:</strong></span><ul><li><span style=\"font-size:12.0pt;\">Serum IgE &gt; 1000 IU/mL</span></li><li><span style=\"font-size:12.0pt;\"><strong>Aspergillus specific IgE</strong> &gt;0.35kU/L(OR) +ve skin test against A. fumigatus. (Test indicates sensitization/Type1 HSN reaction)</span></li></ul></li><li><span style=\"font-size:12.0pt;\"><strong>Supportive Criteria&nbsp;</strong>(\u22652 should be present):</span><ul><li><span style=\"font-size:12.0pt;\">Total eosinophil &gt; 500 cells/mm<sup>3</sup></span></li><li><span style=\"font-size:12.0pt;\">Aspergillus specific IgG</span></li><li><span style=\"font-size:12.0pt;\">Radiology Typical for ABPA</span><ul><li><span style=\"font-size:12.0pt;\"><strong>Central and proximal cylindrical bronchiectasis</strong></span></li><li><span style=\"font-size:12.0pt;\">Alterations predominantly in the upper lobe</span></li><li><span style=\"font-size:12.0pt;\">Nodules</span></li><li><span style=\"font-size:12.0pt;\">Atelectasis</span></li><li><span style=\"font-size:12.0pt;\">Air trapping</span></li></ul></li></ul></li></ol><p style=\"margin-left:72px;\">&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Note: HAM (High attenuation mucus)&nbsp;</strong>is <strong>pathognomonic </strong>feature of ABPA on HRCT</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Cough:&nbsp;</strong>Cough is a typical symptom of ABPA, resulting from airway inflammation and response to mucus production.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Wheezing:&nbsp;</strong>Wheezing in ABPA is due to airway obstruction caused by mucus plugging and inflammation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Raised serum IgE levels:&nbsp;</strong>Elevated IgE levels are a hallmark of ABPA, reflecting the immune system\u2019s hypersensitivity reaction to Aspergillus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Central and proximal bronchiectasis, not distal bronchiectasis, is a characteristic radiological finding in ABPA, helping to differentiate it from other pulmonary conditions. The presence of cough, wheezing, and significantly raised serum IgE levels are supportive of the diagnosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Reference: Harrison 21/Pulmonary infiltrates with eosinophilia/Chap 288</strong></span></p>",
    "correct_choice_id": 44850,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "OlderNEETPG"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 16442,
    "choices": [
      {
        "id": 65728,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nausea</span></span></p>"
      },
      {
        "id": 65729,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypotension</span></span></p>"
      },
      {
        "id": 65730,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sweating</span></span></p>"
      },
      {
        "id": 65731,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Headache</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A man brings his father who became unconscious while working in a field in the hot sun at 42 degrees Celsius in May. On examination, there were no physical signs of dehydration. His serum electrolyte values were normal. The physician found that the body temperature was 106 F. Which of the following symptoms is least likely to be seen in this patient? (FMGE JUNE 2022)</span></span></span></p>",
    "unique_key": "Q5309485",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013061,
    "difficulty_level": "beginner",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Sweating</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In classic heat stroke, patients typically do not sweat. This differentiates it from exertional heat stroke and heat exhaustion. The patient is likely to exhibit symptoms like nausea, hypotension, and headache.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Nausea:</span></strong><span style=\"font-size:12.0pt\"> Common in heat stroke.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypotension:</span></strong><span style=\"font-size:12.0pt\"> Can occur due to dehydration and vasodilation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Headache:</span></strong><span style=\"font-size:12.0pt\"> A common symptom of heat stroke.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In classic heat stroke, sweating is usually absent.</span></span></span></p>",
    "correct_choice_id": 65730,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "FMGE"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11353,
    "choices": [
      {
        "id": 45378,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antiarrhythmics</span></span></span></p>"
      },
      {
        "id": 45379,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV NaHCO3</span></span></span></p>"
      },
      {
        "id": 45380,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Propranolol</span></span></span></p>"
      },
      {
        "id": 45381,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Phenytoin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient on antidepressants presented to you with hypotension. An ECG was done, which showed wide QRS complexes and right axis deviation. How will you manage this patient? (Neet pg 2022)</span></span></span></p>",
    "unique_key": "Q1539203",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012941,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. IV NaHCO3</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient presents with symptoms indicative of tricyclic antidepressant (TCA) overdose, which includes hypotension, wide QRS complexes, and right axis deviation on the ECG. TCAs can block sodium channels in the heart, leading to QRS widening and the potential for serious arrhythmias. They also have anticholinergic effects, which can contribute to the clinical picture.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The first-line treatment for TCA overdose, especially in the presence of cardiac toxicity such as wide QRS complexes, is intravenous sodium bicarbonate (IV NaHCO3). Sodium bicarbonate works by alkalinizing the blood, which helps to overcome the sodium channel blockade caused by TCAs. It also increases the extracellular sodium concentration, which can help stabilize cardiac cell membranes and improve conduction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12pt\"><strong>A.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Antiarrhythmics</strong>: While antiarrhythmics might be considered in other cases of cardiac arrhythmias, they are not the first-line treatment for TCA overdose. In fact, some antiarrhythmic drugs can worsen the condition by further blocking sodium channels or prolonging the QT interval.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12pt\"><strong>C.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Propranolol</strong>: Propranolol is a beta-blocker used to treat high blood pressure and certain types of arrhythmias. However, it is not indicated for the treatment of TCA toxicity and can potentially exacerbate hypotension and cardiac conduction abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12pt\"><strong>D.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Phenytoin</strong>: Phenytoin is an anticonvulsant that can also be used for certain types of arrhythmias. However, it is not effective in treating the sodium channel blockade caused by TCAs and is not recommended for managing TCA overdose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The primary treatment for tricyclic antidepressant overdose, especially when presenting with wide QRS complexes and right axis deviation, is intravenous sodium bicarbonate (IV NaHCO3).</span></span></p>",
    "correct_choice_id": 45379,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "RecentNEETPG",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11324,
    "choices": [
      {
        "id": 45262,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Coarctation of aorta</span></span></p>"
      },
      {
        "id": 45263,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atrial septal defect</span></span></p>"
      },
      {
        "id": 45264,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bicuspid aortic valve</span></span></p>"
      },
      {
        "id": 45265,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patent ductus arteriosus</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A male patient had feeble femoral pulses with an upper-limb blood pressure of 186/90 mmHg. Chest X-ray showed enlarged intercostal arteries. What is the likely diagnosis?</span> <span style=\"font-size:12.0pt\">(NEET PG 2021)</span></span></span></p>",
    "unique_key": "Q7506833",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013057,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A. Coarctation of aorta</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coarctation of the aorta is a congenital condition characterized by the narrowing of the aorta, which causes an obstruction to blood flow. This condition leads to high blood pressure in the arteries that are proximal to the narrowing (upper limbs) and lower blood pressure in the arteries distal to the narrowing (lower limbs).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The key findings in this scenario include:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Feeble femoral pulses</span></strong><span style=\"font-size:12.0pt\">: Due to reduced blood flow past the coarctation.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Upper limb hypertension</span></strong><span style=\"font-size:12.0pt\">: Caused by increased resistance proximal to the coarctation.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Chest X-ray showing enlarged intercostal arteries</span></strong><span style=\"font-size:12.0pt\">: These develop as collateral circulation to bypass the coarctation, which can cause rib notching seen on X-ray.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Atrial septal defect (ASD):</span></strong><span style=\"font-size:12.0pt\"> An ASD is a hole in the septum between the heart&#39;s atria. It typically causes a left-to-right shunt and can lead to increased pulmonary blood flow and right heart overload. It does not cause differential blood pressure between limbs or enlarged intercostal arteries.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Bicuspid aortic valve:</span></strong><span style=\"font-size:12.0pt\"> A bicuspid aortic valve is a congenital valve anomaly that can lead to aortic stenosis or regurgitation but does not typically cause differential blood pressure between the limbs or enlarged intercostal arteries.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Patent ductus arteriosus (PDA):</span></strong><span style=\"font-size:12.0pt\"> A PDA is a persistent opening between the aorta and the pulmonary artery. It causes a continuous murmur and can lead to heart failure if significant but does not cause differential blood pressure or enlarged intercostal arteries.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Coarctation of the aorta should be suspected in patients with a significant difference in blood pressure between the upper and lower limbs, feeble femoral pulses, and chest X-ray findings of enlarged intercostal arteries, indicating collateral circulation.</span></span></p>",
    "correct_choice_id": 45262,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "RecentNEETPG"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11222,
    "choices": [
      {
        "id": 44854,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&gt; 130/80 mmHg</span></span></span></span></p>"
      },
      {
        "id": 44855,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&gt; 140/90 mmHg</span></span></span></span></p>"
      },
      {
        "id": 44856,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&gt; 150/100 mmHg</span></span></span></span></p>"
      },
      {
        "id": 44857,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&gt; 160/100 mmHg</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old male patient has been diagnosed with hypertension. On examination, there is no existing cardiovascular disease, no hypertension-mediated organ damage (HMOD), and the renal function is normal. He should be immediately started on pharmacological management if his blood pressure is more than:</span></span> <span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(NEET PG 2018)</span></span></p>",
    "unique_key": "Q8753055",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013180,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. &gt; 160/100 mmHg</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The ISH (International society of HTN) 2020 guidelines were made to help decision making in low-middle income countries.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Presence of ASCVD risk factors, HMOD (HTN mediated organ damage) is an indication to start anti-HTN therapy.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Home BP recording helps in diagnosis of <strong>Masked HTN</strong>, <strong>rule out white-coat effect</strong></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ABPM provides 24-hour trend and fluctuations in BP.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/22/screenshot-2024-07-22-164121.jpg\" style=\"height:417px; width:1000px\" /></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Home BP &gt; 135/85 mmHg </span></span></strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">= HTN</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ABPM cutoffs:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mean Awake (daytime) average &ge; 135/85 mmHg</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">24h average &ge; 130/80 mmHg</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mean Asleep(night) &ge; 120/70 mmHg</span></span></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BP drops at night by (10-20%), morning surge &ndash; Steep increase, peaks in late afternoon.</span></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Best observed in ABPM&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Ambulatory BP monitoring)<strong>:</strong></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal Dip: 10-20 % at night</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Extreme Dip &gt; 20%</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-dippers &lt; 10%&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(A/w Activation of RAAS)</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Risers: BP raise</span></span></strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase mortality risk among Non-Dippers and Risers.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immediate pharmacological treatment for hypertension in patients without additional cardiovascular risk factors or organ damage should commence when blood pressure levels exceed 160/100 mmHg, according to the ISH 2020 guidelines. This approach helps to target treatment to those most likely to benefit from immediate intervention, balancing the benefits and risks of pharmacotherapy.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reference: ISH2020, AHA2017 HTN guidelines</span></span></strong></p>",
    "correct_choice_id": 44857,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "OlderNEETPG",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 84340,
    "choices": [
      {
        "id": 335932,
        "text": "<p>Stroke involving the middle cerebral artery</p>"
      },
      {
        "id": 335933,
        "text": "<p>Stroke involving the posterior cerebral artery</p>"
      },
      {
        "id": 335934,
        "text": "<p>Aneurysm of the vertebral artery</p>"
      },
      {
        "id": 335935,
        "text": "<p>Aneurysm of the basilar artery</p>"
      }
    ],
    "text": "<p>Which of the following vascular events is most closely associated with pure word deafness? (NEET PG 2015)</p>",
    "unique_key": "Q1678697",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012960,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><strong>Correct Answer: A. Stroke involving the middle cerebral artery</strong></p><p>&nbsp;</p><p><strong>Explanation:</strong></p><p>&nbsp;</p><p>Pure word deafness results from damage to the auditory association cortex in the temporal lobe. The inferior division of the middle cerebral artery supplies the temporal cortex and Wernicke's area. Pure word deafness presents with intact fluency, lost comprehension specifically to spoken language, lost repetition, but intact naming - a distinctive pattern caused by focal damage to auditory language processing pathways, which are within the MCA territory.</p><p>&nbsp;</p><p><strong>Other Options:</strong></p><p>&nbsp;</p><p><strong>Option B. Stroke involving the posterior cerebral artery</strong>: PCA strokes typically cause visual field defects, and when affecting the dominant hemisphere may cause alexia without agraphia, but not pure word deafness as the PCA supplies primarily visual processing areas.</p><p>&nbsp;</p><p><strong>Option C. Aneurysm of the vertebral artery</strong>: Vertebral artery lesions typically cause lateral medullary syndrome with symptoms like vertigo, ipsilateral facial sensory loss, and contralateral body sensory loss, not language disorders.</p><p>&nbsp;</p><p><strong>Option D. Aneurysm of the basilar artery</strong>: Basilar artery lesions produce brainstem syndromes with cranial nerve palsies and long tract signs, not selective auditory comprehension deficits.</p><p>&nbsp;</p><p><strong>Educational Objective:</strong></p><p>&nbsp;</p><p>&nbsp;Pure word deafness is a distinctive language disorder involving selective impairment of spoken language comprehension with preserved other language functions, resulting from lesions to the temporal auditory processing areas in the middle cerebral artery territory.</p>",
    "correct_choice_id": 335932,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "OlderNEETPG"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 20253,
    "choices": [
      {
        "id": 80973,
        "text": "<p><span style=\"font-size:12.0pt;\">Spironolactone</span></p>"
      },
      {
        "id": 80974,
        "text": "<p><span style=\"font-size:12.0pt;\">Hydrochlorothiazide</span></p>"
      },
      {
        "id": 80975,
        "text": "<p><span style=\"font-size:12.0pt;\">Metoprolol</span></p>"
      },
      {
        "id": 80976,
        "text": "<p><span style=\"font-size:12.0pt;\">Prazosin</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A patient is a known case of hypertension and is on multiple antihypertensive drugs. His ECG is shown below. Which drug is responsible for the following ECG? (NEET PG 2023)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/30/screenshot-2024-07-30-143631.jpg\" alt=\"\" width=\"500\" height=\"259\"></span></p>",
    "unique_key": "Q9140673",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013059,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans.&nbsp;A. Spironolactone</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The ECG shows tall, tented T waves, absent P waves (atrial standstill), and a severely widened QRS complex. These are classic signs of severe hyperkalemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Spironolactone&nbsp;</strong>is a potassium-sparing diuretic that can cause hyperkalemia. It is known for increasing potassium levels in the blood by inhibiting the effects of aldosterone, leading to decreased excretion of potassium in the urine.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Therefore, the drug most likely responsible for the ECG findings is Spironolactone due to its potent potassium-sparing effects leading to severe hyperkalemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Hydrochlorothiazide</strong>: Causes hypokalemia, not hyperkalemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Metoprolol:</strong> Can cause mild hyperkalemia but not to the extent seen in the ECG.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Prazosin:</strong> Does not affect potassium levels significantly.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Spironolactone, a potassium-sparing diuretic, can cause severe hyperkalemia, which is characterized by tall, tented T waves, absent P waves, and widened QRS complexes on an ECG.</span></p>",
    "correct_choice_id": 80973,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased",
      "RecentNEETPG"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 11366,
    "choices": [
      {
        "id": 45430,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Megacolon</span></span></span></p>"
      },
      {
        "id": 45431,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Parathyroid adenoma</span></span></span></p>"
      },
      {
        "id": 45432,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mucosal neuroma</span></span></span></p>"
      },
      {
        "id": 45433,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Marfanoid habitus</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is not seen in MEN 2B syndrome? (Neet pg 2022)</span></span></span></p>",
    "unique_key": "Q5594578",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013058,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Parathyroid adenoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Parathyroid adenomas</span></strong><span style=\"font-size:12.0pt\"> are not seen in MEN 2B. Parathyroid adenomas are typically associated with MEN 1 and MEN 2A syndromes, where hyperparathyroidism is a common feature due to the involvement of the parathyroid glands.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Multiple Endocrine Neoplasia type 2B (MEN 2B) is a genetic syndrome characterized by specific clinical features. It is also known as the &quot;<strong>Triple M syndrome</strong>&quot; because it typically presents with the following:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Mucosal Neuromas:</span></strong><span style=\"font-size:12.0pt\"> These are benign growths on the mucous membranes and are a hallmark of MEN 2B.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Marfanoid Habitus:</span></strong><span style=\"font-size:12.0pt\"> This refers to a body habitus resembling Marfan syndrome, with features like long limbs, a tall, slender build, and hyperflexible joints.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Medullary Thyroid Carcinoma (MTC):</span></strong><span style=\"font-size:12.0pt\"> This is a type of thyroid cancer commonly associated with MEN 2B.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Other features that can be seen in MEN 2B include pheochromocytomas (tumors of the adrenal glands) and ganglioneuromas (tumors of the nerve cells).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12pt\"><strong>A.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Megacolon:&nbsp;</strong>Megacolon can be associated with MEN 2B due to the presence of ganglioneuromatosis affecting the gastrointestinal tract.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12pt\"><strong>C.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Mucosal Neuroma:&nbsp;</strong>As mentioned, mucosal neuromas are a classic feature of MEN 2B and one of the reasons it is called &quot;triple M syndrome.&quot;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12pt\"><strong>D.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Marfanoid Habitus:&nbsp;</strong>This characteristic physical appearance is commonly seen in MEN 2B patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MEN 2B syndrome, also known as &quot;triple M syndrome,&quot; is characterized by mucosal neuromas, marfanoid habitus, and medullary thyroid carcinoma, but does not involve parathyroid adenomas.</span></span></span></p>",
    "correct_choice_id": 45431,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual",
      "RecentNEETPG"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 47613,
    "choices": [
      {
        "id": 190063,
        "text": "<p><span style=\"font-size:12.0pt;\">Thyrotoxicosis</span></p>"
      },
      {
        "id": 190064,
        "text": "<p><span style=\"font-size:12.0pt;\">Hypercarbia</span></p>"
      },
      {
        "id": 190065,
        "text": "<p><span style=\"font-size:12.0pt;\">Hemiballismus</span></p>"
      },
      {
        "id": 190066,
        "text": "<p><span style=\"font-size:12.0pt;\">Hypoxia</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">The patient is having the following hand movements. Which of the following conditions is responsible?&nbsp; (</span>FMGE Jan 2024)</p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/06/screenshot-2024-06-05-170640.png\" alt=\"\" width=\"300\" height=\"404\"></span></p>",
    "unique_key": "Q6855529",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012947,
    "difficulty_level": "intermediate",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Hypercarbia</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The hand movements shown in the image are characteristic of asterixis or flapping tremors, which is a form of negative myoclonus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Asterixis is most commonly associated with hepatic encephalopathy but can also be seen in other conditions such as hypercarbia (CO2 narcosis).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Thyrotoxicosis:&nbsp;</strong>This condition typically presents with fine tremors rather than the flapping tremors seen in asterixis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Hemiballismus:&nbsp;</strong>This condition involves violent, involuntary movements of one side of the body, not the flapping tremors associated with asterixis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Hypoxia:&nbsp;</strong>While hypoxia can cause various neurological symptoms, it is not specifically associated with asterixis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Asterixis, or flapping tremors, is a form of negative myoclonus often associated with hepatic encephalopathy and hypercarbia (CO2 narcosis). Recognizing these characteristic hand movements can help identify underlying conditions such as hypercarbia. \u200b</span></p>",
    "correct_choice_id": 190064,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "FMGE",
      "ImageBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 47614,
    "choices": [
      {
        "id": 190067,
        "text": "<p><span style=\"font-size:12.0pt;\">Migraine</span></p>"
      },
      {
        "id": 190068,
        "text": "<p><span style=\"font-size:12.0pt;\">Tension headache</span></p>"
      },
      {
        "id": 190069,
        "text": "<p><span style=\"font-size:12.0pt;\">Cluster headache</span></p>"
      },
      {
        "id": 190070,
        "text": "<p><span style=\"font-size:12.0pt;\">Malingering</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A woman presented with unilateral pulsatile headache, photophobia, phonophobia, and nausea, which is exaggerated on skipping her meals. What is your diagnosis?</span></p>",
    "unique_key": "Q7594678",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013064,
    "difficulty_level": "beginner",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Migraine</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The patient presents with a unilateral, pulsatile headache accompanied by photophobia (sensitivity to light), phonophobia (sensitivity to sound), and nausea. These are classic features of a migraine.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Additionally, the headache is exacerbated by skipping meals, a known trigger for migraines. Other common triggers include stress, certain foods, and hormonal changes.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Tension headache:&nbsp;</strong>This type of headache is usually bilateral, non-pulsatile, and described as a band-like tightness around the head. It does not typically present with photophobia, phonophobia, or nausea.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Cluster headache:&nbsp;</strong>Cluster headaches are characterized by severe, unilateral pain around the eye, often accompanied by autonomic symptoms such as tearing, nasal congestion, and redness of the eye. They do not typically involve photophobia, phonophobia, or nausea.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Malingering:&nbsp;</strong>This refers to the intentional production of false or grossly exaggerated physical or psychological symptoms, motivated by external incentives such as avoiding work or obtaining drugs. There is no indication in the question to suggest malingering.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Migraine is characterized by unilateral, pulsatile headaches accompanied by photophobia, phonophobia, and nausea, and can be triggered by factors such as skipping meals, stress, and certain foods. Recognizing these features is crucial for accurate diagnosis and treatment.</span></p>",
    "correct_choice_id": 190067,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "FMGE"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 16441,
    "choices": [
      {
        "id": 65724,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Constrictive pericarditis</span></span></p>"
      },
      {
        "id": 65725,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac tamponade</span></span></p>"
      },
      {
        "id": 65726,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute pericarditis</span></span></p>"
      },
      {
        "id": 65727,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac failure</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 26-year-old male patient, an accident victim started developing difficulty in breathing. On examination, his BP was 80/40 mmHg and pulses were feeble. JVP was found to be elevated with an absent y descent, and heart sounds were muffled. What is the most likely diagnosis? (FMGE JUNE 2022)</span></span></span></p>",
    "unique_key": "Q5287432",
    "question_audio": null,
    "question_video": null,
    "map_id": 35012944,
    "difficulty_level": "beginner",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Cardiac tamponade</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac tamponade presents with Beck&#39;s triad: hypotension, muffled heart sounds, and elevated JVP. The absence of y descent in JVP and the history of trauma further support the diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Constrictive pericarditis:</span></strong><span style=\"font-size:12.0pt\"> Presents with Kussmaul&#39;s sign and pericardial knock.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Acute pericarditis:</span></strong><span style=\"font-size:12.0pt\"> Presents with chest pain and a pericardial friction rub.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cardiac failure:</span></strong><span style=\"font-size:12.0pt\"> Presents with dyspnea, orthopnea, and peripheral edema but does not typically show absent y descent.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac tamponade is diagnosed with Beck&#39;s triad and an absence of y descent in JVP, especially in trauma settings.</span></span></span></p>",
    "correct_choice_id": 65725,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "FMGE"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 16182,
    "choices": [
      {
        "id": 64688,
        "text": "<p><span style=\"font-size:12.0pt;\">Myasthenia gravis</span></p>"
      },
      {
        "id": 64689,
        "text": "<p><span style=\"font-size:12.0pt;\">Huntington chorea</span></p>"
      },
      {
        "id": 64690,
        "text": "<p><span style=\"font-size:12.0pt;\">Amyotrophic lateral sclerosis</span></p>"
      },
      {
        "id": 64691,
        "text": "<p><span style=\"font-size:12.0pt;\">External ophthalmoplegia</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A young male patient presents with ptosis and muscle weakness which reportedly worsens in the evening and improves in the morning. This is relieved by neostigmine. What is the likely diagnosis? (FMGE JAN 2023)</span></p>",
    "unique_key": "Q1929854",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013062,
    "difficulty_level": "beginner",
    "subjects_id": [],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>A) Myasthenia gravis</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Myasthenia gravis is characterized by fluctuating muscle weakness that worsens with activity and improves with rest. The ptosis and muscle weakness worsening in the evening and improving in the morning, along with improvement with neostigmine (a cholinesterase inhibitor), strongly support the diagnosis of myasthenia gravis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Huntington chorea:&nbsp;</strong>Characterized by a <strong>triad of dementia, psychiatric manifestations, and chorea movements</strong>, which are not present in this patient.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Amyotrophic lateral sclerosis (ALS):&nbsp;</strong>Involves both <strong>upper and lower motor neuron signs</strong>, such as atrophied limbs, spasticity, exaggerated deep tendon reflexes, and fasciculations, none of which are described in this case.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. External ophthalmoplegia:&nbsp;</strong>Refers to weakness of the extraocular muscles without the systemic features seen in myasthenia gravis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Fluctuating muscle weakness with diurnal variation and improvement with cholinesterase inhibitors are hallmark features of myasthenia gravis.</span></p>",
    "correct_choice_id": 64688,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "FMGE"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 47501,
    "choices": [
      {
        "id": 189615,
        "text": "<p>Ataxia</p>"
      },
      {
        "id": 189616,
        "text": "<p>Difficulty swallowing</p>"
      },
      {
        "id": 189617,
        "text": "<p>Crossed pattern of sensory loss</p>"
      },
      {
        "id": 189618,
        "text": "<p>Paralysis of the tongue</p>"
      }
    ],
    "text": "<p>Which of the following is NOT a characteristic feature of lateral medullary syndrome (Wallenberg syndrome)?&nbsp;(NEET PG 2015)</p>",
    "unique_key": "Q1849519",
    "question_audio": null,
    "question_video": null,
    "map_id": 35013177,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><strong>Correct Answer: D. Paralysis of the tongue</strong></p><p>&nbsp;</p><p><strong>Explanation:</strong></p><p>&nbsp;</p><p>Lateral medullary syndrome (Wallenberg syndrome) results from occlusion of the vertebral artery or posterior inferior cerebellar artery (PICA), affecting the lateral medulla. Key features include ipsilateral cerebellar signs (ataxia), Horner's syndrome, and sensory deficits with a classic crossed pattern (ipsilateral face and contralateral body). Dysphagia and dysarthria occur due to involvement of the nucleus ambiguus (9th, 10th cranial nerves). However, tongue paralysis (hypoglossal or 12th nerve dysfunction) is notably absent because the hypoglossal nucleus lies medially in the medulla and is not affected in this lateral syndrome.</p><p>&nbsp;</p><p><strong>Other Options:</strong></p><p>&nbsp;</p><p><strong>Option A. Ataxia</strong>: This IS a characteristic feature of Wallenberg syndrome due to involvement of the spinocerebellar tracts and connections to the cerebellum, causing ipsilateral cerebellar signs.</p><p>&nbsp;</p><p><strong>Option B. Difficulty swallowing</strong>: This IS a characteristic feature due to involvement of the nucleus ambiguus which supplies the 9th and 10th cranial nerves, resulting in dysphagia, dysphonia, and impaired gag reflex.</p><p>&nbsp;</p><p><strong>Option C. Crossed pattern of sensory loss</strong>: This IS a classic feature with ipsilateral face sensory loss (from trigeminal nucleus involvement) and contralateral body sensory loss (from spinothalamic tract involvement).</p><p>&nbsp;</p><p><strong>Educational Objective:</strong>&nbsp;</p><p>&nbsp;</p><p>Lateral medullary syndrome produces a distinctive constellation of ipsilateral cerebellar ataxia, Horner's syndrome, and facial sensory loss with contralateral body sensory loss, but spares the hypoglossal nerve (XII), so tongue paralysis is not part of this syndrome.</p>",
    "correct_choice_id": 189618,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "OlderNEETPG"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  }
];
        let quizName = 'Late Night Pyq:Pyt (Medicine-5)';
        const quizFilename = 'late-night-pyq-pyt-medicine-5-9064f321.html';
        let hierarchy = ["Cerebellum", "Mock Test", "Late Night PYQ"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        // --- NEW: History Management ---
        function saveProgress() {
            if (isQuizCompleted) return; // Don't save after completion
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            userHistory[quizFilename] = {
                questionStates,
                stats,
                currentQuestionIndex,
                currentMode,
                status: 'incomplete',
                lastSeen: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }

        function loadProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const savedState = userHistory[quizFilename];
            if (savedState) {
                questionStates = savedState.questionStates;
                stats = savedState.stats;
                currentQuestionIndex = savedState.currentQuestionIndex;
                currentMode = savedState.currentMode;
                console.log('Progress loaded.');
                return true;
            }
            return false;
        }

        function clearProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            if(userHistory[quizFilename]) {
                delete userHistory[quizFilename];
                localStorage.setItem('userHistory', JSON.stringify(userHistory));
                console.log('Previous progress cleared.');
            }
        }

        function markQuizAsCompleted() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const totalQuestions = questionsData.length;
            const correct = stats.correctAnswers || 0;
            
            userHistory[quizFilename] = {
                score: correct,
                total: totalQuestions,
                status: 'completed',
                completedOn: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }
        // --- End of History Management ---

        const urlParams = new URLSearchParams(window.location.search);
        const startAt = parseInt(urlParams.get('startAt'));
        const resume = urlParams.get('resume') === 'true';

        function goBack() {
            if (!isQuizCompleted) saveProgress(); // Save progress before leaving
            window.location.href = document.referrer || 'index.html';
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            if (!isNaN(startAt) && startAt >= 0 && startAt < questionsData.length) {
                currentQuestionIndex = startAt;
            }

            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                processAnswer();
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
            saveProgress(); // NEW: Save on navigation
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            showSolution();
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            stats.correctAnswers = correct; // Update global stats
            stats.incorrectAnswers = incorrect;
            markQuizAsCompleted(); // NEW: Mark quiz as complete in history
            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                clearProgress(); // NEW: Clear history on retake
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                        saveProgress();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (resume) {
                if (loadProgress()) {
                    document.getElementById('modeModal').style.display = 'none';
                    initializeQuiz(); // Resume directly into the saved mode and state
                } else {
                    // If resume fails (e.g., cleared history), start fresh
                    clearProgress();
                    document.getElementById('modeModal').style.display = 'flex';
                }
             } else if (!window.location.pathname.endsWith('custom_quiz.html')) {
                clearProgress(); // Clear old progress if not resuming
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>